Translational Photoacoustic Tomography by Zhou, Yong
Washington University in St. Louis
Washington University Open Scholarship
Engineering and Applied Science Theses &
Dissertations McKelvey School of Engineering
Spring 5-15-2016
Translational Photoacoustic Tomography
Yong Zhou
Washington University in St. Louis
Follow this and additional works at: https://openscholarship.wustl.edu/eng_etds
Part of the Biomedical Commons
This Dissertation is brought to you for free and open access by the McKelvey School of Engineering at Washington University Open Scholarship. It has
been accepted for inclusion in Engineering and Applied Science Theses & Dissertations by an authorized administrator of Washington University Open
Scholarship. For more information, please contact digital@wumail.wustl.edu.
Recommended Citation
Zhou, Yong, "Translational Photoacoustic Tomography" (2016). Engineering and Applied Science Theses & Dissertations. 154.
https://openscholarship.wustl.edu/eng_etds/154
  
WASHINGTON UNIVERSITY IN ST. LOUIS 
School of Engineering and Applied Science 
Department of Biomedical Engineering 
 
Dissertation Examination Committee: Lihong V. Wang, Chair  Mark A. Anastasio Jianmin Cui  Gregory Lanza  Baranidharan Raman Jung-Tsung Shen   
 
 
Translational Photoacoustic Tomography by Yong Zhou 
 
 
A dissertation presented to the  Graduate School of Arts & Sciences of Washington University in partial fulfillment of the requirements for the degree of Doctor of Philosophy 
 
 
 
May 2016 St. Louis, Missouri 
  
  
 
 
 
 
 
 
 
 
 
 
© 2016, Yong Zhou
ii  
Table of Contents 
List of Figures ................................................................................................................................ iv  
List of Tables ................................................................................................................................ vii  
Acknowledgments........................................................................................................................ viii  
ABSTRACT OF THE DISSERTATION ....................................................................................... x 
Chapter 1 Introduction .................................................................................................................... 1  
1.1 Photoacoustic Tomography ............................................................................................. 1 
1.2 Motivation ....................................................................................................................... 2 
Chapter 2 Photoacoustic Microscopy of Blood Diseases ............................................................... 4 
2.1 Optical Clearing-aided Photoacoustic Microscopy with Enhanced Resolution and Imaging Depth in Mouse in Vivo .................................................................................... 4 
2.2 Photoacoustic Microscopy of Jaundice ......................................................................... 11 
2.3 Photoacoustic Microscopy of Red Blood Cell Aggregation ......................................... 26 
2.4 Conclusions ................................................................................................................... 43 
Chapter 3 Pain Syndrome Study with Photoacoustic Tomography in Patients ............................ 45  
3.1 Microcirculatory Changes Identified by Photoacoustic Microscopy in Patients with Complex Regional Pain Syndrome Type I (CRPS-1) after Stellate Ganglion Blocks .. 45 
3.2 Conclusions ................................................................................................................... 55 
Chapter 4 Photoacoustic Flowmetry in Humans .......................................................................... 56  
4.1 Calibration-free Transverse Blood Flow Measurement Based on Time-domain Cross Correlation Using Photoacoustic Microscopy in Vivo .................................................. 56 
4.2 Saline-injection-based Photoacoustic Flowmetry in the Optical Diffusive Regime ..... 75 
4.3 Cuffing-based Photoacoustic Flowmetry in Humans in Depths of the Optical Diffusive Regime .......................................................................................................................... 82 
4.4 Conclusions ................................................................................................................... 87 
Chapter 5 Photoacoustic Tomography of Human Brain Vasculature ........................................... 89 
5.1 Photoacoustic Tomography of Mouse Brain in Vivo .................................................... 89 
5.2 Photoacoustic Tomography of the Human Brain in Vivo ............................................. 91 
iii  
5.3 Conclusions ................................................................................................................... 98 
Chapter 6 Photoacoustic Imaging of Melanoma in Patients ......................................................... 99  
6.1 Handheld Photoacoustic Microscopy to Detect Melanoma Depth in Vivo ................. 100 
6.2 Handheld Photoacoustic Probe to Detect both Melanoma Depth and Volume at High Speed in Vivo ............................................................................................................... 108 
6.3 Handheld Photoacoustic Probe for Noninvasive Determination of Melanoma Depth in Patients ........................................................................................................................ 116  
6.4 Conclusions ................................................................................................................. 119 
Chapter 7 Summary .................................................................................................................... 121  
References ................................................................................................................................... 124  
Vita .............................................................................................................................................. 131  
 
 
  
iv  
List of Figures 
Figure 2.1: System schematic of the optical clearing-aided photoacoustic microscopy (PAM)…. 5 
Figure 2.2: Optical clearing-aided PAM of a coin covered by mouse skin………...........………….6 
Figure 2.3: In vivo PAM of a mouse scalp facilitated by optical clearing…….…..………………...7 
Figure 2.4: Optical clearing reveals more capillaries………………………………………………8 
Figure 2.5: Optical clearing improves the lateral resolution for deep vessels………………...…..10 
Figure 2.6: Schematic of the PAM system…………………………………….………….…..…..14 
Figure 2.7: Absorption spectra of bilirubin, oxyhemoglobin, and deoxyhemoglobin……..…..….17 
Figure 2.8: The measured bilirubin concentration versus the preset concentration………...……..19 
Figure 2.9: Quantitative PAM of tissue-mimicking samples ….………………………………....20 
Figure 2.10: Multi-wavelength PAM of the mixtures with 75% oxygen saturation (sO2)………..21 
Figure 2.11: Multi-wavelength PAM of the mixtures of bilirubin and blood (100% sO2)………..22 
Figure 2.12: PAM of tissue phantoms with various bilirubin concentrations………….………….23 
Figure 2.13: Optical resolution PAM (OR-PAM) schematic…………………...………...………31 
Figure 2.14: Representative PA signals and amplitudes of multiple A-lines………………...….32 
Figure 2.15: Relationships between variance and mean values in phantom experiments………...34 
Figure 2.16: Measurements for different photon count fluctuation coefficients………………….35 
Figure 2.17: Quantitatively measuring particle concentration from different samples …………..36 
Figure 2.18: Measured red blood cell (RBC) counts under the same light fluctuation……...…….37 
Figure 2.19: Measurement of RBC counts in tubing covered by a living mouse ear……………...38 
Figure 2.20: RBC count measurement in blood-filled tubing covered by a mouse ear……..….….39 
Figure 2.21: In vivo RBC count changes in a mouse tail vein when injecting saline…...................40 
Figure 2.22: RBC aggregation induced by 3% Dextran-70 solution…………………………...…41 
Figure 2.23: RBC aggregation measured in vivo………………………………………………....42 
v  
Figure 3.1: Schematic of the OR-PAM and acoustic resolution PAM (AR-PAM) systems………48 
Figure 3.2: AR-PAM vasculature image of the right hand of one patient……………...…………50 
Figure 3.3: OR-PAM vasculature image of a fingertip of one patient……...….……………….…51 
Figure 3.4: Normalized PA signal and average sO2 measured by AR-PAM and OR-PAM………52 
Figure 4.1: Principle of flow measurement by PAM based on cross correlation………………….57 
Figure 4.2: Schematic overview of the flow measurement setup………………..……………..…59 
Figure 4.3: Measured transverse flow velocities using 10-µm-diameter microspheres…………..62 
Figure 4.4: Flow velocities measured using three sizes of microspheres…………………………63 
Figure 4.5: Measured flow velocities with parabolic fits in the depth direction………………….64 
Figure 4.6: Quantification of the maximum measurable velocities………………...……………..66 
Figure 4.7: Quantification of the minimum measurable velocities………...……………………..69 
Figure 4.8: Measured average flow velocities with underlaid chicken tissue................................70 
Figure 4.9: Measured flow velocities of defibrinated bovine blood versus preset values…………71 
Figure 4.10: In vivo blood flow measurements in vessels with different structures………………72 
Figure 4.11: Measurement of flow changes in a curved vessel…………………………………...73 
Figure 4.12: Observation of feature conservation in a vessel bifurcation…………………….….74 
Figure 4.13: Schematic of the photoacoustic tomography system and saline injection…………..77 
Figure 4.14: Steps to extract the flow velocity…………………………………………………...78 
Figure 4.15: Phantom experiments based on saline injection…………………………………….79 
Figure 4.16: In vivo experiments based on saline injection….……………………………………81 
Figure 4.17: Photographs of the photoacoustic (PA) tomography (PAT) system………..……….83 
Figure 4.18: Phantom experiments based on cuffing….………………………………………….84 
Figure 4.19: Photographs of the human experiments……………………………………………..85 
Figure 4.20: Human experiments based on cuffing…….………………………………………...86 
Figure 5.1:  PAT of mouse brain with 5 MHz transducer array at two coronal planes…….………90 
vi  
Figure 5.2: Blood vasculature imaged by a 21 MHz transducer array……...……………………..91 
Figure 5.3: Schematic of human brain imaging system…………………………………………..93 
Figure 5.4: Cortex blood vessel (CBV) phantom experiment…………………………………….94 
Figure 5.5: Superficial blood vessels (SBV) phantom experiment……………………………….95 
Figure 5.6: Phantom experiment with SBVs, chicken tissue, and monkey skin….……………….97 
Figure 6.1: Experimental handheld PAM system……………………………………………….102 
Figure 6.2: Monte Carlo simulations of the old and new PAM systems…....................................103 
Figure 6.3: Spatial resolutions of the current PAM system……….……….…………………….105 
Figure 6.4: Handheld PAM of melanoma phantoms…………………………………………….106 
Figure 6.5: Handheld PAM of melanoma in a nude mouse in vivo……………………………..107 
Figure 6.6: Schematic of the linear transducer array with optical fiber bundle integrated……....109 
Figure 6.7: Simulation of the single focused ultrasonic transducer and the linear array………..110 
Figure 6.8: Response characteristics of the linear-array probe………………………………….111 
Figure 6.9: Linear-array-based PA images of melanoma phantoms…………………………….112 
Figure 6.10: Depth and volume quantification of melanoma phantoms………………………..113 
Figure 6.11: Linear-array-based PA images of ex vivo melanomas…………………………….115 
Figure 6.12: Depth and volume quantification of ex vivo melanomas…………………………..115 
Figure 6.13: Linear-array-based PA images of melanoma acquired in vivo..……………………116 
Figure 6.14: PAT of melanoma in patients…….………………………………………………..117 
Figure 6.15: PAT-measured depth of all melanomas…..………………………………...……...118 
  
vii  
List of Tables 
Table 2.1: Bilirubin concentrations measured by PAM in various phantoms without and with      underlaid mouse skins. ...............................................................................................24 Table 4.1: Flow velocity measurements in vessels with different structures ..............................72 Table 4.2: Flow velocity measurements in a single vessel……………………………………...73 Table 4.3: Flow velocity measurements in a vessel bifurcation ..................................................74  
  
  
viii  
Acknowledgments 
I gratefully thank my mentor, Dr. Lihong V. Wang, for his inspiring guidance, generous support, 
and constant encouragement. I also acknowledge him for helping me establish a high ethical 
standard in research. 
I thank all my collaborators, Dr. Mark Anastasio, Dr. Lynn Cornelius, and Dr. Xiaobin Yi, for 
their work and my committee members for their support of my work. 
I thank all the lab colleagues, especially Dr. Konstantin Maslov, for their contributions and useful 
suggestions to this work. I also thank Prof. James Ballard for his careful editing of this dissertation 
and his years of help. 
 Yong Zhou 
Washington University in St. Louis 
May 2016 
 
  
ix  
 
 
 
 
 
 
 
 
 
 
 
Dedicated to my family. 
 
 
 
 
 
 
 
 
 
 
 
x  
ABSTRACT OF THE DISSERTATION 
Translational Photoacoustic Tomography 
by 
Yong Zhou 
Doctor of Philosophy in Biomedical Engineering 
Washington University in St. Louis, 2016 
Professor Lihong V. Wang, Chair 
 Combining optical excitation and ultrasonic detection, photoacoustic tomography (PAT) offers 
deep imaging with high resolution. With optical excitation, PAT maintains the high contrast of 
optical imaging. Because of the low scattering of ultrasonic waves in tissue, PAT achieves high 
spatial resolution at depths. Several advantages make PAT suitable for clinical application, 
including its scalable penetration and resolution, high optical absorption contrast, fast imaging 
speed, and ability to perform spectral decomposition. Based on different image reconstruction 
mechanisms, PAT can be further divided into two embodiments: raster-scanning-based 
photoacoustic microscopy (PAM) and reconstruction-algorism-based photoacoustic computed 
tomography (PACT). This dissertation aims to advance the direction of translational PAT, 
including both PAM and PACT. 
 
In Chapter 1, I first explain the basic principles of PAM and PACT and then discuss in detail why 
they are suitable for translational studies. The chapter concludes with the motivation of my 
dissertation. 
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Chapter 2 introduces my translational studies in PAM. I first improved the system’s lateral 
resolution and imaging penetration depth by applying an optical clearing technique. With glycerol 
as an optical clearing agent, the imaging performance of optical resolution PAM (OR-PAM) was 
greatly enhanced both in vitro and in vivo. Then I applied PAM in quantifying concentrations of 
blood substances, including red blood cells (RBCs) and bilirubin, and studied related diseases, 
such as RBC aggregation and jaundice. After building a model to statistically analyze 
photoacoustic signals for absolute measurement of red blood cell count, I developed multi-
wavelength decomposition algorithms and implemented multi-wavelength PA imaging to map 
bilirubin concentration.  
 
Chapter 3 describes studies of complex regional pain syndrome (CRPS) in patients with both OR-
PAM and acoustic resolution PAM (AR-PAM). Blood vasculature and oxygen saturation (sO2) 
were imaged in eight adult patients with CRPS. Patients’ hands and cuticles were imaged both 
before and after stellate ganglion block (SGB) for comparison. For all patients, both vascular 
structure and sO2 could be assessed by PAM. In addition, more vessels and stronger signals were 
observed after SGB. The results show that PAM can help diagnose and monitor CRPS. 
 
Chapter 4 introduces my work on flow measurement both in mice and humans. It first discusses 
improving the flow measurement accuracy by a new technique – cross-correlation-based 
flowmetry. This technique is based on OR-PAM and can effectively remove the particle size 
induced measurement error. I demonstrated this technique both in phantom and in vivo 
experiments in mice. To achieve flow measurement in the optical diffusive regime, I further 
developed two methods: saline-injection-based and cuffing-based flowmetries. The saline-
xii  
injection-based method is especially pertinent to monitoring blood flow velocity in patients 
undergoing intravenous infusion, while the cuffing-based one is suitable for both patients and 
healthy people. 
 
Chapter 5 presents my work on brain imaging, including both mouse and human brains in vivo. To 
achieve deep mouse brain imaging, I first used a ring transducer array (5 MHz center frequency) 
with an acoustic reflector. Blood vessels from the bottom of the mouse brain could be imaged, and 
many key features were detected, such as diving vessels, the superior sagittal sinus, and the 
posterior cerebral artery. However, the image contrast was not high due to the poor spatial 
resolutions of the system. To improve the image quality, I later used a linear array system with a 
21 MHz center frequency. By rotating the linear array, more striking images were acquired. For 
the human imaging project, I successfully imaged blood vessel phantoms through an adult human 
skull. 
 
Chapter 6 describes my work on melanoma imaging and depth measurement in patients. Two 
different systems were used in this project: a handheld AR-PAM system and a handheld linear 
array system. While the former is cheaper, the latter provides much faster imaging and a larger 
acceptance angle. With the array system, we successfully imaged melanomas in patients and 
achieved more accurate depth measurement than incisional biopsy in clinics. 
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Chapter 1 Introduction 
1.1 Photoacoustic Tomography 
Photoacoustic tomography (PAT), also called optoacoustic tomography, is a three-dimensional 
(3D) imaging modality based on the photoacoustic (PA) effect [1-4]. Although the PA effect was 
discovered more than a century ago by Alexander Graham Bell, it has found applications in 
biomedical imaging only in the last decade or so. Nowadays, PAT is one of the largest research 
areas in biomedical optics, and is still growing rapidly [5]. 
Harnessing both rich optical absorption contrast and high ultrasonic resolution, PAT is a hybrid 
imaging modality that can image deep tissues. While pure optical imaging modalities can also 
detect optical absorption by monitoring intensity variations in transmitted or reflected light, their 
sensitivities are usually two orders of magnitude lower than that of PAT [6]. In addition, because 
acoustic waves scatter much more weakly than light in biological tissues, they can propagate a 
greater distance than photons without losing their original propagation directions, providing PAT 
with high spatial resolution at depths. While pure ultrasonic imaging can also achieve high spatial 
resolution in deep tissues, its mechanical contrast is incapable of providing certain physiological 
parameters, such as the oxygen saturation of hemoglobin and the metabolic rate of oxygen [7, 8]. 
Based on different image reconstruction mechanisms, PAT can be further divided into two 
embodiments: reconstruction-algorism-based photoacoustic computed tomography (PACT) [9] 
and raster-scanning-based photoacoustic microscopy (PAM) [10, 11]. For PACT, the light is 
expanded to illuminate the whole object to be imaged. PA signals are acquired at multiple locations 
around the object, either by using a transducer array or by scanning a single-element transducer to 
simulate an array. Next, back-projecting all the PA data, similar to traditional CT or PET imaging, 
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generates PA images of the object. Different from reconstruction-based methods, the focused-
scanning scheme of PAM usually focuses both the optical excitation and acoustic detection. If the 
optical focus is tighter than the acoustic focus, the technique is called optical resolution 
photoacoustic microscopy (OR-PAM); otherwise, it is called acoustic resolution photoacoustic 
microscopy (AR-PAM). In both cases, each laser pulse generates a one dimensional photoacoustic 
image (A-line) along the axial direction. Raster-scanning laterally and then piecing together all the 
A-lines provides a 3D PA image.  
Several advantages make PAT suitable for clinical application. First, it can image deep: up to 7 
cm deep images have been reported with a spatial resolution of a few hundred micrometers [1]. 
Second, it detects a rich variety of optical absorbers, both exogenous (e.g., methylene blue) and 
endogenous. So far, many endogenous contrasts have been imaged with high sensitivity, such as 
hemoglobin [12], myoglobin [13], DNA and RNA [14, 15], water [16, 17], lipid [18], cytochrome 
c [19], bilirubin [20], and melanin [21]. Third, similar to ultrasound imaging, PAT has scalable 
resolution. Thus, both fine structures (such as organelles) and global features (such as organs) can 
be detected with the same contrast [22-25]. Fourth, because different chemical compositions have 
different absorptions, features can be distinguished by multi-wavelength imaging. For example, in 
vivo human nevi and their surrounding vasculature have been successfully differentiated by PAT 
[25]. Fifth, because hemoglobin is confined within blood vessels, vasculature can be imaged with 
high contrast-to-noise ratio.  
1.2 Motivation 
This work aims to advance PAT to translational studies and applications. First, we want to refine 
the technology in order to achieve high spatial resolution and deep penetration (Chapter 2), which 
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can be realized by optical clearing technique. We then applied PAT to study blood vasculature 
diseases by measuring absolute red blood cell count and in mapping bilirubin (Chapter 2). Second, 
we want to study the complex regional pain syndrome (CRPS) in patients (Chapter 3). Due to a 
lack of proper diagnostic tools, the prognosis of CRPS is primarily based on clinical observation. 
The objective of this work is to evaluate PAM for assisting diagnoses and monitoring the progress 
and treatment outcome of CRPS. Third, we want to improve current blood flow measuring 
techniques and push them to humans (Chapter 4). Fourth, we want to push the direction of brain 
imaging both in mice and humans, because brain imaging is the key to study neuro activities 
(Chapter 5). Fifth, we want to achieve deep melanoma imaging and accurately measure melanoma 
depth in patients (Chapter 6). Melanoma depth is a key parameter in its diagnosis and treatment, 
but current incisional biopsy usually cannot provide accurate depth information. Because the deep 
penetration of PAT and strong absorption from melanin, PAT should be able to image melanoma 
with high contrast and accurately measure melanoma depth. 
  
4  
Chapter 2 Photoacoustic Microscopy of Blood Diseases 
This chapter describes the technique improvement in PAM, which was achieved by using optical 
clearing technique. Then we applied PAM in studying two types of blood diseases: red blood cell 
aggregation and jaundice. Work in this chapter has been published in Optics Letters and Journal 
of Biomedical Optics [20, 26, 27].   
2.1 Optical Clearing-aided Photoacoustic Microscopy with Enhanced Resolution and Imaging Depth in Mouse in Vivo 
Background  Photoacoustic microscopy (PAM) is a recently developed imaging modality that can 
provide structural [1], molecular [20], functional [28-31], and metabolic information [7]. Based on 
its focusing mechanism, PAM can be divided into two different implementations: acoustic-
resolution PAM and optical-resolution PAM (OR-PAM). In OR-PAM, the lateral resolution is 
determined by the diffraction-limited optical focusing. As photons travel in tissue, the focusing 
capability degrades due to optical scattering. In addition, the maximum penetration depth of OR-
PAM in biological tissue is mainly limited by the optical transport mean free path, affected by both 
absorption and scattering. Since the tissue scattering is typically an order of magnitude larger than 
the absorption, it is the scattering that predominantly limits the penetration depth of OR-PAM [32]. 
To reduce the scattering, tissue optical clearing (TOC) techniques have been widely used in many 
high resolution optical imaging modalities, such as laser speckle contrast imaging and optical 
coherence tomography. The basic mechanism of TOC is to diffuse a high-refractive-index optical 
clearing agent (OCA) into the tissue, which reduces the refractive index mismatch between 
intracellular components and extracellular fluids and thus decreases the scattering. In addition, 
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tissue dehydration caused by OCAs has also been used to explain TOC [33]: on one hand, it 
increases refractive index matching due to decreased volume fraction of free water in the interstitial 
fluid; on the other hand, it increases packing of scatters, which may engender spatial correlations 
between scatterings, both of which reduce scattering further. In this Letter, for the first time, we 
demonstrate that both the imaging depth and lateral resolution of OR-PAM can be enhanced by 
using a glycerol–water solution (88% vol./vol.), which is a commonly used OCA in TOC. 
 
Figure 2.1 System schematic used in the optical clearing-aided optical resolution photoacoustic microscopy (OR-
PAM). CorL, correction lens; OL, objective lens; RAP, right-angle prism; RhP, rhomboid prism; SOL, silicone oil 
layer; UT, ultrasonic transducer. 
Methods  We implemented this idea on a previously reported OR-PAM system (Figure 2.1). 
Briefly, a tunable dye laser (CBR-D, Sirah, GmbH) pumped by a Nd:YLF laser (INNOSAB, 
Edgewave, GmbH) was the light source. After being focused by a condenser lens, filtered by a 
pinhole, and reflected by a mirror, the laser beam was finally focused by an objective lens into the 
sample. Ultrasonic detection was achieved by a wideband ultrasonic transducer (V214-BC, 
Panametrics-NDT Inc.), which was placed confocally with the optical objective lens. Each laser 
pulse yielded a one-dimensional depth resolved PA image (A-line) by recording the time course 
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of PA signals. A three-dimensional (3D) image was obtained by raster scanning the sample and 
piecing together A-lines. 
 
Figure 2.2 Optical clearing-aided PAM of a coin covered by mouse skin. (a) Photograph of the one cent coin used in 
the experiment. (b)–(d) PA images of the coin at different times during optical clearing. (e) Time course of the PA 
amplitude averaged over the whole image during optical clearing. The higher PA amplitude indicates that the optical 
clearing increased penetration depth. 
Phantom results  First, in a phantom experiment, a U.S. penny [Figure 2.2(a)] covered by a piece 
of freshly harvested mouse skin was imaged at 570 nm. The phantom was immersed in the 
glycerol–water solution. As shown in the baseline image [Figure 2.2(b)], there were almost no PA 
signals from the coin because of the strong scattering of the mouse tissue. During optical clearing, 
the PA signals from the coin became stronger and stronger, and more features became resolvable, 
as shown from Figures 2.2(c) and 2.2(d). Figure 2(e) shows the average total PA signal amplitude 
from the coin versus time; after 250 min, the amplitude increased more than threefold over the 
baseline value. Note that the PA signals were still increasing at the point when we stopped the 
experiment. This phantom experiment clearly illustrates that the scattering of the tissue was 
reduced by optical clearing, and thus the penetration depth was enhanced. 
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Figure 2.3 In vivo PAM of mouse scalp facilitated by optical clearing. (a) PAM image before optical clearing. (b) 
PAM image with capillaries after optical clearing. (c) PAM image with parts of capillary layer digitally removed 
after optical clearing. (d)–(f) PA amplitude along the red dashed line in (a)–(c). MAP image along the y axis (g) 
before and (h) after optical clearing. (i) PA amplitude averaged along the x direction of (g) (blue line) and (h) (red 
dashed line). 
Results  Next, we used a nude mouse in an in vivo experiment. All experimental animal procedures 
were carried out in conformance with the laboratory animal protocol approved by the Animal 
Studies Committee of Washington University in St. Louis. Because the diffusion of glycerol across 
the epidermal layer is very slow, we directly injected the glycerol–water solution into the mouse 
scalp to create a local optical clearing window. Figures 2.3(a) and 2.3(b) show the maximum-
amplitude-projection (MAP) of the PA images of blood vessels in the mouse scalp before and after 
optical clearing, respectively. For a better visualization of the deeper vessels in the scalp, we 
digitally removed most of the superficial capillaries seen in Figure 2.3(b), with the result shown in 
Figure 2.3(c). From Figures 2.3(a)–2.3(c), we can see a clear PA signal amplitude enhancement 
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after optical clearing. Three representative lines were taken from Figures 3(a)–3(c) for further 
comparison, as shown in Figures 2.3(d)–2.3(f). The averaged PA amplitude had increased by about 
eight times after optical clearing. 
 
Figure 2.4 Optical clearing reveals more capillaries. (a) and (b) Close-ups of PAM images in the red dashed boxes in 
Figs. 3(a) and 3(b). (c) and (d) PA amplitudes along the red dashed lines in (a) and (b). 
We also quantified the optical clearing effect along the depth direction, as shown in Figures 2.3(g) 
and 2.3(h). To quantify the total signal enhancement after optical clearing, the averaged PA signal 
amplitude along the depth was calculated and is shown in Figure 2.3(i). Based on Beer’s law, the 
fitted attenuation coefficients before and after optical clearing were 57.4 and 103.1 cm-1, 
respectively. At first glance, the attenuation appears to have increased after optical clearing. 
However, since dehydration due to optical clearing caused the total thickness of the tissue to 
decrease by about 2.57 times [Figures 2.3(g) and 2.3(h)], the scatter and absorber number density 
should increase by about 2.57 times. If both the scattering and absorption cross section had 
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remained constant after optical clearing, the attenuation coefficient should have increased by 2.57 
times rather than the 1.80 times observed in the experiment. Thus, the scattering or absorption 
cross section was reduced after optical clearing. Because optical clearing did not affect the 
absorption cross section, we concluded that the 0.77 times less increase in the attenuation 
coefficient resulted from the decrease in the scattering cross section. 
The enhanced PA detection sensitivity after optical clearing enabled better capillary imaging 
[Figure 2.3(b)]. Figures 2.4(a) and 2.4(b) are close-up images of the red dashed-square areas in 
Figures 2.3(a) and 2.3(b), respectively. The large vessels in the periphery of both images indicate 
that they are from the same area in the mouse scalp. As shown in Figure 2.4(a), very few capillaries 
can be detected before optical clearing. However, after optical clearing, more capillaries can be 
distinctly observed, as shown in Figure 2.4(b). As shown in Figures 2.4(c) and 2.4(d), the vessel 
density increased by about 10 times after clearing, and the averaged PA signal amplitude from 
individual capillaries increased by a factor of 22. The much denser capillaries and stronger PA 
amplitudes in Figure 2.4(d) indicate that, after optical clearing, the local laser fluence at the 
capillaries was increased. There were two possible reasons for the increased local laser fluence: 
(1) enhanced focusing on these capillaries due to the dehydration-induced shrinkage of the tissue 
and (2) reduced scattering loss. As shown in Figure 2.3(i), because of dehydration, the averaged 
thickness of the tissue decreased from about 0.88 to 0.37 mm. Assuming the light beam intensity 
had a Gaussian shape, we estimated that the average fluence increase caused by shrinkage was 
about 5 times. Therefore, we can conclude that the remaining 4.4-fold increase of the PA signal 
amplitude was due to the decreased scattering coefficient. Because the background noise remained 
constant during the experiment, the noise-equivalent sensitivity depended only on the PA signal 
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amplitude. Therefore, sensitivity should also increase 4.4 times due to the decreased scattering 
coefficient. 
 
Figure 2.5 Optical clearing improves the lateral resolution for deep vessels. (a) Close-up of PAM image in the green 
dashed box in Figure 2.3(a). (b) Close-up of PAM image in the green dashed box in Figure 2.3(c). (c) and (d) PA 
amplitudes along the red dashed lines in (a) and (b). (e) Combined curves in (c) and (d) after normalization. 
We further analyzed the lateral resolution enhancement after optical clearing. By zooming in on 
the deeper vessels in Figures 2.3(a) and 2.3(b), we found that the vessels before optical clearing 
were much more blurred than those after optical clearing, as shown in Figures 2.5(a) and 2.5(b). 
Again, the averaged PA amplitude was increased by about 5 times [Figures 2.5(c) and 2.5(d)]. 
More importantly, we also estimated the lateral resolution improvement by comparing the vessel 
diameters. As shown in Figure 2.5(e), a representative vessel had nominal diameters of 75 and 30 
μm before and after clearing, respectively. We can see that measured vessel diameter decreased at 
least by 2.5 times after optical clearing. Because the measured vessel diameter was the convolution 
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of the actual lateral resolution with the true vessel diameter, the actual resolution improvement 
should be better than 2.5 times. 
Discussion  There are several widely used OCAs, such as glycerol [33], glucose [34], and 
propylene glycol. Among these agents, glycerol has both good clearing efficiency and a long 
effective time. In addition, because glycerol has also been widely used in the medical, 
pharmaceutical, and chemical fields, it can be easily accessed. Thus, in all experiments, we elected 
to use glycerol as the OCA to reduce tissue scattering. To achieve a relatively good clearing result 
and to reduce the potential tissue damage caused by dehydration, a diluted glycerol–water solution 
(88% vol./vol.) was used. A higher glycerol concentration may enhance the clearing effect with a 
higher risk of tissue damage [35]. 
Because glycerol penetrates very slowly through epidermal tissue, we directly injected the glycerol 
solution into the tissue to accelerate optical clearing. However, injection may lead to side effects, 
such as bleeding and edema [35]. To use glycerol without injection, we can explore either physical 
or chemical approaches, such as using a microneedle array or a dimethyl sulfoxide (DMSO) 
admixture, respectively. Because high-concentration glycerol may block blood flow [36, 37], other 
safer optical clearing media, such as PEG-400 mixed with thiazone [38, 39], should be explored 
in the future. 
2.2 Photoacoustic Microscopy of Jaundice 
Background  Bilirubin is a yellow-orange breakdown product of red blood cells. Elevated 
bilirubin levels (>2.5–3.0 mg/dL) in blood streams and tissues are always associated with 
physiological disorders, such as jaundice and hyperbilirubinemia [40, 41]. A high bilirubin 
concentration may cause kernicterus [42], a kind of irreversible brain damage in newborn babies. 
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Thus, measuring the bilirubin level plays an important role in the diagnosis of jaundice and other 
diseases. Besides quantifying the average bilirubin level, determination of its spatial distribution 
provides additional information for such diagnoses. It has been suggested that measuring both the 
serum and the transcutaneous bilirubin levels concurrently will enable a more accurate 
identification of jaundice [43, 44]. In addition, measuring the bilirubin distribution may provide 
opportunities to study kernicterus (by analyzing the movement of bilirubin across the blood-brain 
barrier and its deposition into the brain tissue) [43, 45, 46], to estimate the age of bruises in forensic 
medicine [47], and to reveal the bilirubin photochemistry interaction during phototherapy [48, 49].  
Current techniques for bilirubin measurement have various limitations. The conventional approach 
to measuring bilirubin concentration involves extracting blood, which is invasive, and only the 
total serum bilirubin level can be monitored, without any spatial information. Noninvasive 
monitoring methods include diffuse reflectance [50-52] and hyperspectral imaging [47, 53]. The 
former senses the overall concentration of bilirubin in the skin without spatial resolution, whereas 
the latter maps the relative bilirubin distribution without quantification. Therefore, we still lack a 
technique for quantitative imaging of bilirubin. 
Since it was first introduced in 2005, photoacoustic microscopy (PAM) has been proven to be a 
promising modality for both structural and functional imaging. In PAM, the object is irradiated by 
a short-pulsed laser. Following the absorption of light, a temperature rise generates an initial 
pressure rise, which is propagated as a photoacoustic wave. This photoacoustic wave is then 
detected by a focused ultrasonic transducer. Because the initial pressure is proportional to the local 
energy absorbed, photoacoustic measurements with multiple optical wavelengths can provide 
spectral information of optical absorption. Based on the different absorption spectra of 
oxyhemoglobin and deoxyhemoglobin, the oxygen saturation of hemoglobin (sO2) has been 
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successfully quantified by PAM with high accuracy and spatial resolution. In addition, PAM has 
shown its feasibility to detect other intrinsic contrasts in biological tissue, such as DNA and RNA 
in nuclei, water, lipid, cytochrome c, and melanin.  
The motivation of this work is to image bilirubin distribution quantitatively by using PAM. We 
first demonstrated that our PAM system was capable of measuring the absorption spectra of 
bilirubin and blood (including oxyhemoglobin and deoxyhemoglobin). Based on the absorption 
spectra, proper wavelengths were chosen to measure pure bilirubin samples and mixed bilirubin-
blood samples. Then the root-mean-square error of prediction (RMSEP) in both the pure and mixed 
samples was measured. Last, the bilirubin distributions in tissue-mimicking samples were imaged 
both without and with underlaid mouse skins. We showed for the first time that bilirubin, both 
inside and outside the blood vessels, can be imaged quantitatively by PAM with relatively high 
accuracy. 
Methods and Materials   A free-space transmission-mode PAM system was utilized for bilirubin 
detection, as shown in Figure 2.6. The laser pulse (5 ns pulse width, 1 KHz pulse repetition rate), 
with a wavelength tunable from 210 nm to 2600 nm, was generated by an integrated diode-pumped 
Q-switched laser and optical parametric oscillator system (NT242-SH, Ekspla). The pulse was 
then filtered by 2 mm iris (ID25SS, Thorlabs) to remove the nonuniform rim. After being reflected 
by a mirror (PF10-03-G01, Thorlabs), focused by a condenser lens (LA4380, Thorlabs), and 
filtered by a 50 µm pinhole (P50C, Thorlabs), the light beam was focused by an optical objective 
with 0.3 numerical aperture (NA). The excited photoacoustic waves were detected by a focused 
ultrasonic transducer (40 MHz central frequency, 80% bandwidth, and 0.5 NA). The ultrasonic 
transducer and optical objective were aligned coaxially and confocally to achieve high sensitivity. 
Each laser pulse yielded a one-dimensional depth-resolved image (A-line) by recording the arrival 
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times of photoacoustic signals. A two-dimensional (2D) scanning stage (PLS-85, MICOS) held 
the sample and provided lateral scanning. We rendered our result in the form of a 2D maximum 
amplitude projection (MAP) image, which was produced by projecting the maximum amplitude 
of the 3D image along the axial direction. 
 
Figure 2.6 Schematic of the PAM system. 
In the experiments, bilirubin powder (B4126, Sigma-Aldrich) was dissolved in dimethyl sulfoxide 
solution (Fisher Scientific) and further diluted by water. To prepare the pure tissue-mimicking 
sample, the bilirubin solution was mixed with 5% gelatin (G1890, Sigma-Aldrich) and 1% 
intralipid (Fresenius Kabi). The congealed sample had a thickness of 0.5 mm and an optical 
scattering coefficient of approximately 100 cm-1. To prepare the mixed sample (to mimic blood 
vessels), the bilirubin solution was mixed with lysed bovine blood with a 75% sO2 (905-250, Quad 
Five). Oxygenated hemoglobin was prepared by mixing oxygen with lysed bovine blood (905-
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250, Quad Five) for 2 h. Deoxygenated hemoglobin was prepared by adding 33 mg of sodium 
hydrosulfite (71699-50, Sigma-Aldrich) to 10 ml of lysed bovine blood (905-250, Quad Five). The 
75% sO2 blood was prepared by mixing oxyhemoglobin and deoxyhemoglobin at a ratio of 1:3 
and measured by an oximeter for validation. To mimic a blood vessel, the mixture was then 
contained in a microtube (made of platinum-cured silicone) with an inner diameter of 300 µm and 
an outer diameter of 600 µm (60985-700, VWR). To mimic the varied physiological levels in real 
patients, phantoms were prepared with different concentrations of bilirubin. 
The PAM system was calibrated with pure samples with preset bilirubin concentrations of 2, 4, 6, 
and 8 mg/dL, and with a preset blood concentration of 148 g/L for quantification. The sO2 was set 
to be ~75%. The A-lines from each sample (prepared as described previously) were averaged 
10,000 times at each optical wavelength. The peak PA signal amplitude versus the wavelength was 
used to separately calculate the concentration by weighted least squares fit with the photoacoustic 
spectra of bilirubin and blood. We repeated this calibration procedure for the samples overlaid 
with mouse skins of different thicknesses (200 µm, 400 µm, and 600 µm) in order to obtain 
quantitative results at these depths.  
Both the calibration and concentration measurements can be described by the following equations: 
     ( ) ( )bi bi bi bik C                                (2.1) 
( ) ( )ox ox ox oxk C                       (2.2) 
( ) ( )de de de dek C     ,                 (2.3) 
where φbi(λ), φox(λ), and φde(λ) are the  wavelength-dependent photoacoustic signal amplitudes 
normalized with the laser pulse energy (recorded in mV/nJ) of bilirubin, oxyhemoglobin, and 
deoxyhemoglobin, respectively; εbi(λ), εox(λ), and εde(λ) are the wavelength dependent molar 
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absorption coefficients of bilirubin, oxyhemoglobin, and deoxyhemoglobin, respectively; Cbi, Cox, 
and Cde are the concentrations of bilirubin,  oxyhemoglobin, and deoxyhemoglobin, respectively; 
and kbi, kox, and kde are the calibration factors for bilirubin, oxyhemoglobin, and deoxyhemoglobin, 
respectively. For calibration, Cbi, Cox, and Cde were known, while kbi, kox, and kde were calculated 
by weighted least squares fitting. kbi, kox, and kde were slightly different due to differences among 
the samples. For concentration measurement, kbi, kox, and kde were from the calibration, while Cbi, 
Cox, and Cde were calculated by weighted least squares fitting. Here the variances of the 
photoacoustic signals are used in the least squares fits as weighting terms.  
For the mixture of bilirubin and blood, we can calculate all bilirubin, oxyhemoglobin, and 
deoxyhemoglobin concentrations by fitting the bilirubin and blood absorption spectra to the 
photoacoustic signals: 
                            ( ) ( ) ( ) ( )bi bi bi ox ox ox de de dek C k C k C             ,                    (2.4) 
where φ(λ) is the wavelength-dependent photoacoustic signal amplitude.  
To describe the measurement precision, the RMSEP of the concentration can be defined as  
  2 2RMSEP s rC e e  .                                                (2.5) 
where systematic error es and random error er are defined as 
  2
1
( ) /ns i iie M C n  ,                                                (2.6) 
and                                                        2
1
/nr iie M n  ,                                                        (2.7) 
respectively. Here, Ci, Mi, and δMi are the preset concentration, mean measured concentration, and 
measurement standard deviation of the ith sample, respectively; and n is the total number of 
samples. RMSEP denotes the measurement error by combining in quadrature both the systematic 
error and random error. The systematic error describes the root-mean-squared difference between 
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the measurement and the actual value, mostly likely originating from instrument calibration errors. 
The random error describes the measurement fluctuation without averaging, most likely 
originating from noise. 
 
Figure 2.7 Absorption spectra of bilirubin, oxyhemoglobin, and deoxyhemoglobin. (a) Relative absorption spectra of 
bilirubin, oxyhemoglobin, and deoxyhemoglobin measured by PAM scaled by fitting to the spectrophotometer 
measurement. (b) The molar extinction coefficient ratio between bilirubin, oxyhemoglobin, and deoxyhemoglobin in 
the wavelength range from 460 nm to 490 nm. µbili: relative absorption coefficient of bilirubin. εbili: molar extinction 
coefficient of bilirubin. µoxy: relative absorption coefficient of oxyhemoglobin. εoxy: molar extinction coefficient of 
oxyhemoglobin. µdeoxy: relative absorption coefficient of deoxyhemoglobin. εdeoxy: molar extinction coefficient of 
deoxyhemoglobin. SP: spectrophotometer. 
To quantitatively map the concentration distribution of bilirubin in various samples, the samples 
were imaged at multiple wavelengths, and each pixel of the co-registered multi-wavelength images 
was analyzed by the above method as described by Equation 2.4. To obtain the statistical ‘volume-
averaged’ data, we set a threshold of five times the noise level to separate the sample and the 
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background, and then averaged the signals within each sample to get our final mean concentration 
value. 
Results  We used PAM to measure the absorption spectra of bilirubin, oxyhemoglobin, and 
deoxyhemoglobin by using pure bilirubin (2 mg/dL) and blood (37 g/L) solutions, respectively.  
The relative optical absorption at each wavelength was calculated from the average PA signal 
amplitude normalized by the laser pulse energy. Figure 2.7(a) shows the absorption spectra of 
bilirubin, oxyhemoglobin, and deoxyhemoglobin measured by the PAM system, all fitting well to 
the absorption spectra measured with a spectrophotometer (Cary 50 Bio UV/ Visible, VARIAN). 
The residual systematic difference between the bilirubin spectra may have resulted from 
instrument errors. Because bilirubin has a relatively high absorption in the wavelength range from 
430 nm to 490 nm, we chose this range for the bilirubin measurement. Likewise, because the 
absorption ratio between bilirubin and blood is relatively high in the wavelength range from 460 
nm to 490 nm [Figure 2.7(b)], which enables an easier differentiation of bilirubin from blood, we 
chose this range for the blood absorption spectrum detection. Also, the wavelength range from 540 
nm to 545 nm was chosen, where blood has high absorption [Figure 2.7(a)], but bilirubin has 
almost no absorption. We used theses component spectra measured by PAM as the standard to 
decompose spectra of mixtures for the concentrations of bilirubin, oxyhemoglobin, and 
deoxyhemoglobin. 
We quantified the accuracy of bilirubin concentration measurements by PAM in both pure and 
mixed samples. The tissue-mimicking samples for the pure bilirubin measurements were the same 
as those used in the calibration (bilirubin concentrations of 2, 4, 6, and 8 mg/dL; thickness of 200 
µm). The optical wavelength was varied from 430 nm to 460 nm. The bilirubin concentration could 
be calculated simply from the PA signal amplitudes after calibration, as shown in Figure 2.8(a). 
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The RMSEP of the concentration was calculated by Eq. (5) to be 0.52 mg/dL for the pure bilirubin 
samples, where the systematic error is 0.17 mg/dL and the random error is 0.49 mg/dL.  
 
Figure 2.8 The measured bilirubin concentration (C) of each sample versus the preset concentration. (a) Pure 
bilirubin phantom. Bilirubin solution mixed with (b) 75% sO2 blood and (c) 100% sO2 blood. Red circle: 
experimental measurement of C. Blue solid line: ideal fit if the measured and preset concentrations are identical. 
Black circle: experimental measurement of sO2. Green dashed line: preset sO2. For the bilirubin blood mixture 
sample with 75% sO2 and 100% sO2, the RMSEP of the concentration for bilirubin is calculated to be 1.04 mg/dL 
and 0.83 mg/dL, respectively. 
For the mixed-sample measurement, we used four samples with bilirubin-to-blood concentration 
ratios of 2, 4, 6, and 8 mg/dL of bilirubin to 148 g/L of blood. Two wavelength ranges were chosen 
for this experiment. One was from 460 nm to 490 nm, where the molar extinction coefficient ratio 
between bilirubin and blood is relatively high, as shown in Figure 2.7(b). The other was from 540 
nm to 545 nm, where blood has high absorption, but bilirubin has almost no absorption. The 
measurements for the mixed samples with 75% and 100% sO2 are shown in Figure 2.8(b) and 
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Figure 2.8(c), respectively. According to Equation 2.5, the RMSEP value of the bilirubin for the 
75% sO2 mixed samples was calculated to be 1.04 mg/dL, where the systematic error is 0.14 mg/dL 
and the random error is 1.03 mg/dL. For the 100% sO2 mixed samples, the RMSEP value was 0.86 
mg/dL, where the systematic error was 0.62 mg/dL and the random error was 0.55 mg/dL. Also, 
as shown in Figures 2.8(b) and 2.8(c), the sO2 value can be recovered in the mixture. 
 
Figure 2.9 Quantitative PAM of tissue-mimicking samples containing bilirubin with varied concentrations. (a) 
Bilirubin distribution image. From top to bottom in the image, the sample concentrations are 1, 2, 3, 4, and 5 mg/dL, 
respectively. (b) Volume-averaged bilirubin concentrations from the PAM measurements in each sample. Red circle: 
experimental measurement. Blue line: ideal fit if the measured and preset concentrations are identical. 
Next, we implemented quantitative PAM of pure bilirubin samples. Five congealed samples with 
different volume-averaged bilirubin concentrations (1, 2, 3, 4, and 5 mg/dL) were prepared as 
described above, which covered the normal and elevated bilirubin levels in humans. Each sample 
was cylindrical with a diameter of about 0.5 mm (determined by the inner diameter of the metal 
tube used as the sample mold), and the space between the samples was filled with ultrasonic gel. 
With a step size of 2 µm, a 3 mm by 0.3 mm area was scanned at 430 nm wavelength, where 
bilirubin has a strong absorption, to acquire PAM images of bilirubin distributions. The volume-
averaged concentrations of bilirubin in the samples were set to be 1 mg/dL to 5 mg/dL, from the 
top to the bottom of Figure 2.9(a). The measured average concentration of bilirubin in each sample 
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was in accordance with the preset concentration, as shown in Figure 2.9(b). The results show that 
the PAM system not only can measure the bilirubin concentration but also can provide its spatial 
information in the pure bilirubin sample. 
 
Figure 2.10 Multi-wavelength PAM of the mixtures of bilirubin and blood (75% sO2). (a) Quantitative PAM images 
at six optical wavelengths. (b) Bilirubin distribution image calculated from the multi-wavelength PAM images. 
From top to bottom in the image, the bilirubin concentrations are 2, 4, 6, 8, and 10 mg/dL, respectively, whereas the 
blood concentration is 148 g/L.  (c) Volume-averaged bilirubin concentration from the PAM measurements in each 
tube. Red circle: experimental measurement. Blue line: ideal fit if the measured and preset concentrations are 
identical. 
We also detected the bilirubin spatial distribution in the mixed samples with 75% sO2. 
Wavelengths of 460, 470, 480, 490, 540, and 545 nm were selected. Solutions with bilirubin-to-
blood ratios of 2, 4, 6, 8 and 10 mg/dL to 148 g/L were prepared, corresponding to both normal 
and elevated ratios in physiology. Five tubes with the same diameters as in the previous experiment 
held the mixture samples. Here, a 4 mm by 0.5 mm area was scanned with a step size of 2 µm. The 
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PAM images of the mixed solutions acquired at each wavelength are shown in Figure 2.10(a). 
Since blood has much higher absorption than bilirubin, it is difficult to distinguish the bilirubin 
concentrations based merely on a single image. However, based on the multi-wavelength images, 
the image of the bilirubin concentration distribution can be calculated and is shown in Figure 
2.10(b). The average bilirubin-to-blood ratios in the sample, from top to bottom, ranged from 2 
mg/dL to 10 mg/dL of bilirubin to 148 g/L of blood. The measured average concentrations of 
bilirubin are in fair accordance with the preset concentrations, as shown in Figure 2.10(c).  
 
Figure 2.11 Multi-wavelength PAM of the mixtures of bilirubin and blood (100% sO2). (a) Bilirubin distribution 
image calculated from the multi-wavelength PAM images. From top to bottom in the image, the bilirubin 
concentrations are 2, 4, 6, 8, and 10 mg/dL, respectively, whereas the blood concentration is 148 g/L.  (b) Volume-
averaged bilirubin concentration from the PAM measurements in each tube. Red circle: experimental measurement. 
Blue line: ideal fit if the measured and preset concentrations are identical. 
Similarly, we detected the bilirubin spatial distribution in the mixed samples with 100% sO2. The 
image of the bilirubin concentration distribution is shown in Figure 2.11(a). The measured average 
concentrations of bilirubin are shown in Figure 2.11(b). The results in Figures 2.10 and 2.11 
illustrate that PAM can quantitatively image bilirubin distributions in the presence of blood. 
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Figure 2.12 PAM of tissue phantoms with varied bilirubin concentrations. The three images are acquired with  
underlaid mouse skins with thickness of 200 μm (a), 400 μm (b), and 600 μm (c), respectively. For every image, the 
upper two tubes are bilirubin solutions mixed with blood. The concentration ratios between bilirubin and blood are 8 
mg/dL : 148 g/L and 4 mg/dL : 148 g/L, respectively. The lower two samples are pure bilirubin phantoms with 
concentrations of 4 mg/dL and 2 mg/dL, respectively. 
Finally, to further demonstrate the ability of PAM to measure bilirubin distribution in biological 
tissue, pure and mixed samples underlaid by mouse skins (light illuminated from the bottom) were 
imaged simultaneously. Fresh mouse skins, with thicknesses of 200 µm, 400 µm, and 600 µm, 
were used to underlay the samples. Pure bilirubin samples with concentrations of 2 mg/dL and 4 
mg/dL and mixed samples with bilirubin-to-blood ratios of 4 mg/dL and 8 mg/dL to 148 g/L (75% 
sO2) were prepared. In each experiment, a 4 mm by 0.5 mm area was scanned, with a step size of 
2 µm (Figure 2.12). In every image of Figure 2.12, the upper two samples are bilirubin solutions 
mixed with blood (with concentration ratios of 8 mg/dL and 4 mg/dL to 148 g/L), and the lower 
two samples are pure bilirubin phantoms (with concentrations of 4 mg/dL and 2 mg/dL). For pure 
and blood-mixed bilirubin, the detection procedure was the same as discussed before. The skin 
thicknesses in Figures 2.12(a), (b), and (c) were 200, 400, and 600 µm, respectively. From Figure 
2.12, we can see that the measured bilirubin concentrations were consistent with the preset values 
when the skin thicknesses were 200 and 400 µm. However, when the thickness of skin increased 
to 600 µm, the measurements were less accurate. Table 2.1 shows bilirubin measurements between 
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phantoms without and with underlaid mouse skins is shown. With skin underlaid (200 µm and 400 
µm), the measurement accuracy is similar to that without skin underlaid. However, when the skin 
thickness increases to 600 µm, the results are less accurate because of the low signal-to-noise ratio 
(SNR). Thus, at least a 400 µm penetration depth can be achieved by our method in measuring 
bilirubin concentration both inside blood vessels (i.e., the mixed samples) and outside blood 
vessels (i.e., the pure samples). 
 
Table 2.1 Bilirubin concentrations measured by PAM in various phantoms without and with underlaid mouse skins. 
Discussion  In these tissue phantom experiments, the quantitative measurements down to 400 µm 
in depth rely on accurate calibration. The influences of ultrasound refraction/reflection and depth 
dependence of fluence may be very difficult to calibrate in future in vivo experiments. However, 
since bilirubin is located shallow in the skin (tens of micrometers, both in the dermis and 
epidermis), we should be able to map bilirubin distribution in vivo with reasonable accuracy within 
tens of micrometers of depth, similar to measuring oxygen saturation (sO2) in vivo.     
There are four main types of absorbers in the visible spectral range in the skin: oxyhemoglobin, 
deoxyhemoglobin, bilirubin, and melanin. In blood vessels, absorption mainly originates from 
oxyhemoglobin, deoxyhemoglobin, and bilirubin; while outside the blood vessel absorption is 
mainly due to bilirubin and melanin. As our work was focused on demonstrating the feasibility of 
PAM measurements of bilirubin concentration and distribution, the influence of melanin in the 
Bilirubin C measured by PAM
Pure bilirubin phantoms Blood mixed solutions
2 mg/dL 4 mg/dL 4 mg/dL 8 mg/dL
No skin 2.40 ± 0.68 3.88 ± 1.14 4.03 ± 0.76 8.21 ± 1.50
200 µm 2.05 ± 1.02 3.97 ± 2.03 4.45 ± 1.33 7.74 ± 2.89
400 µm 2.23 ± 1.23 3.73 ± 1.77 4.03 ± 1.13 7.72 ± 2.16
600 µm 3.00 ± 0.48 3.01 ± 0.65 6.09 ± 1.30 5.83 ± 1.86
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pure bilirubin was not taken into account. However, in principle, if we choose at least four optical 
wavelengths, each absorber’s concentration can be quantified. 
As discussed above, to measure the pure bilirubin distribution, only one wavelength is needed. For 
bilirubin mixed with blood, with sufficient SNR, three wavelengths are enough to differentiate the 
concentration of bilirubin from that of blood. But more wavelengths (as used in our experiments) 
provide more data to obtain a more accurate least squares fit because the SNR is improved. 
However, using more wavelengths to measure the sample would take longer, which could be an 
important concern for in vivo imaging. Thus, there is a trade-off between accuracy and speed. To 
reduce the measurement time, voice-coil scanning [54] or laser scanning [55] can be utilized in the 
future. 
A transmission-mode PAM system was used to detect bilirubin distribution in this work. For 
clinical applications, it is difficult to measure the skin by transmission-mode PAM because of the 
large thickness of the tissue. Thus, it is preferred to use reflection-mode PAM, which can be 
achieved by the use of a parabolic mirror with a central hole for light delivery [56]. 
When a healthy human with a very low bilirubin level in blood is imaged, PAM currently may not 
be able to provide accurate quantitative results. But PAM can complement other techniques, such 
as blood analysis, by providing the spatial distribution of bilirubin noninvasively. With further 
development of our technique, we expect to detect relative levels of albumin conjugated bilirubin, 
which is of clinical significance [57]. Blood analyses can be used to measure the total serum 
bilirubin level for a quantitative validation. 
 
26  
2.3 Photoacoustic Microscopy of Red Blood Cell Aggregation 
Background  Over the past few years, PAM has been proven to be capable of structural, 
functional, molecular, and metabolic imaging. In PAM, the object is illuminated by a short-pulsed 
laser beam. Following the absorption of light, the increased temperature generates an initial 
pressure rise, which propagates as PA waves and is detected by an ultrasonic transducer. Because 
the initial pressure is directly proportional to the absorbed optical energy density ( )A r  (J∙m-3) in 
the tissue, which is the product of the optical fluence ( )F r  (J∙m-2) and the optical absorption 
coefficient ( )a r   (m-1), multi-wavelength PA measurements can provide spectral information of 
optical absorption. Moreover, because it is essentially background free for blood-vessel imaging, 
PAM has better imaging contrast than other back-scattering-based optical imaging modalities. So 
far, PAM has shown its viability in detecting many intrinsic contrasts in biological tissues, such as 
hemoglobin, bilirubin, DNA and RNA in nuclei, lipid, cytochromes, and melanin. To obtain the 
intrinsic contrast property ( )a r  , we need to compensate for the extrinsic quantity ( )F r . However, 
the optical fluence is usually unknown because of the light attenuation in tissue. Therefore, it is 
generally challenging to provide quantitative PA studies of, for example, oxygen metabolism.  
Currently, the optical fluence can be compensated for either invasively [58] or noninvasively 
[59-64]. In the invasive method, an optical absorber with a priori known absorption spectrum is 
placed close to the target of interest and used as a reference. PA amplitude from the target of 
interest is normalized by the measured PA amplitude of this reference absorber. A noninvasive 
method involves solving both optical diffusion and PA wave equations. However, the inverse 
problems are computationally intensive and ill-posed due to optical diffusion. In another 
( )F r
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noninvasive method, the temporal profiles of PA signals are used to determine the absolute 
absorption coefficient [65-68]. However, the acoustic attenuation and the limited bandwidth of the 
transducer may distort the PA signals. Thus, the direct fitting method may be inaccurate. To avoid 
this issue, our group has proposed to use acoustic spectra to determine the absolute absorption 
coefficient [69, 70].  
Here we present another quantitative approach to measure absolute absorber concentrations by 
statistical analyses of PA signals. To obtain a fluence-independent detection, the particle count in 
the detection volume needs to be small enough so that PA signal fluctuation due to the particle 
Brownian motion is dominant compared to other fluctuating sources, such as laser intensity 
fluctuation, electronic thermal noise, and photon shot noise. This method is analogous to 
fluorescence correlation spectroscopy and dynamic light scattering (also known as photon 
correlation spectroscopy). The former has been widely used to measure the fluorescence intensity 
fluctuations, while the latter has been used to measure the scattered light intensity fluctuations. 
The part of dissertation is organized as follows. We first developed a model to describe the 
relationship between the measured PA signal and the particle count. The principle was then 
demonstrated experimentally. After samples of varied microsphere concentrations were studied, 
red blood cells (RBCs) were measured to show that our method can be applied to biological 
samples. Finally, we performed in vivo experiments to demonstrate the potential of our method in 
biological applications. 
Methods and Materials  Particle fluctuation in a detection volume caused by Brownian motion 
is governed by Poisson distribution [71]. Thus, the variance of the particle count ( pN ) equals its 
mean, i.e.,  
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( ) ( )p pVar N E N .                      (2.8) 
where Var() denotes the variance, and E() denotes the mean. Fluctuations of the particle count 
contribute to the PA signal fluctuations, which were assessed with multiple laser pulses. However, 
other sources could also lead to fluctuations in the PA signal, such as laser intensity fluctuation, 
electronic thermal noise, and photon shot noise. Because the photon shot noise is much smaller 
than the electronic thermal noise in PAM, it can be ignored. In a typical PA system, a photodiode 
(PD) is used to compensate for the laser pulse energy fluctuations. A beam sampler is used to 
extract a small portion of light into PD, while the remaining light illuminates the sample. The 
output of photodiode amplitude ( PDA ) can be expressed as  
PD PD ph PDA k RN n  ,                    (2.9) 
where PDk  is the efficiency of conversation from photons to voltage; R  is the percentage that light 
reflects from the beam sampler; phN  is the photon count of the incident light; and PDn  is the PD 
electronic thermal noise after the mean value is subtracted. The photon count fluctuation is 
typically specified as a few percent of average pulse energy, hence the variance of photon count 
fluctuation can be assumed to be proportional to the square of mean photon counts:  
2 2( ) ( )ph phVar N E N ,                    (2.10) 
where   denotes the photon count fluctuation coefficient. Parameter ߙ is a property of the laser 
but it can be controlled to some extent by discarding laser pulses outside of the predetermined 
range of pulse energies.  
Because the thermal noise is zero-mean, the mean and variance of PDA are derived from Equation 
2.9 as 
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( ) ( )PD PD phE A k RE N ,                 (2.11) 
  2 2( ) ( ) ( )PD PD ph PDVar A k R Var N Var n  .                  (2.12) 
Based on Equations 2.11 and 2.12, we have 
2 2( ) ( ) ( )PD PD PDVar A E A Var n  .                                     (2.13) 
Equation 2.13 shows a parabolic relationship between ( )PDVar A  and ( )PDE A .  
Similar to the analysis of PD, the PA amplitude ( PAA ) can be expressed as 
PA PA p ph PAA k N TN n  ,                        (2.14) 
where PAk  is a constant factor including Grueneisen parameter, heat conversion percentage, 
absorption cross section, and other minor contributors; pN  is the particle count inside the detection 
volume; T  is the percentage that light transmits through the beam sampler; and PAn  is the 
electronic thermal noise of the ultrasonic transducer. Note that R + T is slightly less than unity due 
to absorption and scattering loss. 
Based on Equation 2.14, the mean and the variance of PAA  are  
   ( ) ( ) ( )PA PA p phE A k E N TE N ,                      (2.15) 
2
2 2 2 2
( ) ( ) ( )
[ ( ) ( ) ( ) ( ) ( ) ( )] ( )
PA PA p ph PA
PA p ph ph p p ph PA
Var A k Var N TN Var n
k T Var N E N Var N E N Var N Var N Var n
 
    .   (2.16) 
Substituting Equation 2.8 into Equation 2.16, we have 
2 2 2 2
2 2 2 2 2 2
( ) [ ( ) ( ) ( ) ( ) ( ) ( )] ( )
[ ( ) ( ) ( ( ) ( )) ( )] ( )
PA PA p ph ph p p ph PA
PA p ph p p ph PA
Var A k T E N E N Var N E N E N Var N Var n
k T E N E N E N E N E N Var n
   
    .       (2.17) 
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When ܧ( ௣ܰ) ≫ ߙିଶ, we have 
 2 2 2 2 22 2( ) ( ) ( ) ( )( ) ( )
PA PA p ph PA
PA PA
Var A k E N T E N Var n
E A Var n


 
  .                      (2.18) 
The ratio between the mean squared and the variance of PAA  is the power-based signal-to-noise 
ratio (SNR): 
 
2
2
2 2 2 2 2 2
( )
( )
( ( ) ( ))
[ ( ) ( ) ( ( ) ( )) ( )] ( )
PAPA PA
PA p ph
PA p ph p p ph PA
E ASNR Var A
k E N TE N
k T E N E N E N E N E N Var n

   
.                       (2.19) 
Defining 2 ( )( )PAth PA
E ASNR Var n , and substituting it into Equation 2.19, we have  
2
2 2
1 1 1 1(1 )( ) ( )
1 1(1 ) ( )
PA p p th
p th
SNR E N E N SNR
E N SNR

 
   
    .                                         (2.20) 
Since ߙଶ ≪ 1, we get 
                                      21 1 1( )PA p thSNR E N SNR    .                                                          (2.21) 
Equation 2.21 can be discussed in two different cases. In case 1, when particles are dense enough 
so that ܧ( ௣ܰ) ≫ ߙିଶ, we have 
 21 1
PA thSNR SNR   . (2.22) 
PASNR  approaches 2   when thSNR  increases. In case 2, when particles are sparse enough so 
that ܧ( ௣ܰ) ≪ ߙିଶ, we have 
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 1 1 1( )PA p thSNR E N SNR  . (2.23) 
PASNR  approaches ( )pE N  when thSNR  increases. Using Equation 2.23 or more generally 
Equation 2.21, one can measure the expected value of the absolute particle count. In addition, if 
ܧ( ௣ܰ) ≪ ܴܵܰ௧௛, Equation. 2.23 reduces to  
 ( )PA pSNR E N . (2.24) 
Thus, the measurement outcome is independent of the laser fluence. Although our model is derived 
for static particle suspension, it is also valid for flowing particles, because the temporal statistics 
of particle count fluctuations in a static medium are equivalent to the spatial statistics of the particle 
count fluctuations in a flowing medium. 
 
Figure 2.13 OR-PAM schematic. BS, beam splitter; ConL, condenser lens; CorL, correction lens; EP, eyepiece; ND, 
neutral density filter; OL, objective lens; PD, photodiode; PH, pinhole; RAP, right-angle prism; RhP, rhomboid 
prism; SOL, silicone oil layer; UT, ultrasonic transducer; WT, water tank. 
We validated this idea using our optical-resolution PAM (OR-PAM) system shown in Figure 2.13. 
A tunable dye laser (CBR-D, Sirah, GmbH.), pumped by a Nd:YLF laser (INNOSAB, Edgewave, 
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GmbH.) at a 1 kHz pulse repetition rate, provides nanosecond laser pulses. The laser beam is 
filtered by a 50-µm-diameter pinhole and focused into the sample by a microscope objective lens 
(numerical aperture is 0.1). An acoustic-optical beam combiner, composed by two prisms 
sandwiching a layer of silicone oil, provides the acoustic-optical coaxial alignment. Acoustic 
detection is achieved with an ultrasonic transducer (V214-BC, Panametrics-NDT, Inc.) and a 
spherically focused acoustic lens, which is placed confocally with the optical objective lens. The 
detected PA signal is then amplified, digitized, and stored. Unlike confocal and two-photon 
microscopy, depth scanning is not needed in OR-PAM for volumetric imaging. A three-
dimensional image is obtained by raster scanning the sample and piecing together the depth-
resolved one-dimensional images (A-lines). So far, this OR-PAM system has achieved a lateral 
resolution of ~5 µm and an axial resolution of ~15 µm with an imaging depth of ~1 mm. Thus, the 
detection volume is about 500 µm3 based on 1/e excitation beam width. In all experiments, plastic 
tubing with inner diameter of 300 μm was used to flow the liquid sample. A fast flow speed of 9 
mm/s was applied to the fluid in the tubing to avoid potential heat aggregation or photobleaching, 
and to make sure the multiple PA signals were completely independent.  
 
Figure 2.14 Representative PA signals (a) and PA amplitudes (b) of multiple A-lines with the same incident laser 
energy for each particle count. 
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To calculate ( )PAVar A  and ( )PAE A , for each particle count, we measured 1500 A-lines with the 
same incident laser energy. Representative A-lines and corresponding PA amplitudes are shown 
in Figures 2.14(a) and (b), respectively. Thus, ( )PAVar A  and ( )PAE A  can be obtained by 
calculating the variance and mean of the PA amplitudes. The background of each A-line inside the 
dashed box in Figure 2.14(a) was used to calculate the electronic thermal noise PAn . Then we tuned 
the neutral density filter, shown in Figure 2.13, to change the incident laser energy. Thus, different  
PASNR  and thSNR  could be obtained. Meanwhile, for each PA A-line, we monitored the incident 
energy by using a PD. Similarly, we could also calculate ( )PDVar A  and ( )PDE A  after 1500 
measurements. By selecting PA A-lines with corresponding ( )PDE A  only in a predetermined 
range, the photon count fluctuation α can be controlled. If ܧ( ௣ܰ) ≪ ߙିଶ, the absolute particle 
count can be quantified based on Equation 2.23 or Equation 2.24. 
Lysed bovine blood was used for the experiment with large particle counts. It is estimated that 
there are about one billion hemoglobin molecules in the detection volume,26 which satisfies the 
condition that ( )pE N  is much larger than 2   for Equation 2.22. For small particle counts, 
defibrinated whole bovine blood was used instead for the experiment. In whole blood, RBCs, 
instead of hemoglobin molecules, constitute the particles moving in and out of the detection 
volume. Since there are only a few RBCs in the detection volume, ( )pE N  will be much smaller 
than 2  , satisfying the condition for Equaiton 2.23. 
To demonstrate quantitative particle count measurement, we prepared samples with different 
particle concentrations. Since we require that particle count fluctuation be dominant in the PA 
signal fluctuation, two different sizes of red dyed microspheres were used to make the samples: a 
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0.5 μm diameter particle with a stock concentration of ~3.64 × 1011 particles per milliliter (2.5% 
w/w), and a 1 μm diameter particle with a stock concentration of ~4.55 × 1010 particles per milliliter 
(2.5% w/w). The smaller particle stock solution was diluted by 2 and 4 times, while the larger 
particle stock solution was diluted to 8 and 16 times the stock concentration of the smaller particle 
solution. 
 
Figure 2.15 Relationships between (a) Var(APD) and E(APD), (b) Var(APA) and E(APA), (c) E(APA) and E(APD) as 
estimated from the experimental data. Fitting equation for (a): Var(APD) = α2 × E2(APD) + 2631, where α = 0.0567, 
coefficient of determination R2 = 0.9994. Fitting equation for (b): Var(APA)  = α2 × E2(APA) + 7508, where α = 
0.0576, R2 = 0.9974. Fitting equation for (c): E(APA) = 0.6656 × E(APD) - 190.7, R2 = 0.9964. (a) and (b) show that 
when the particle count is sufficiently large, both Var(APA) and Var(APD) follow a parabolic relationship with E(APA) 
and E(APD), respectively. The coefficients α for PD and PA are almost identical, both due to the photon count 
fluctuation. (c) shows a good linearity between E(APA) and E(APD). 
We used defibrinated bovine blood in two experiments: an ex vivo experiment and an in vivo 
mimicking experiment. For the ex vivo experiment, defibrinated bovine blood with four different 
concentrations was prepared. The original undiluted defibrinated bovine blood (150 g/L) was 
serially diluted to 3/4, 1/2, and 1/4 of the original concentration. Since there were too few RBCs 
in the original resolution voxel of OR-PAM, we increased the detection volume to 1.2×10-5 mm3 
by defocusing the light beam. For the simulated in vivo experiment, the original undiluted 
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defibrinated bovine blood (150 g/L) was serially diluted to 1/2 and 1/4 of the original 
concentration. 
Results  Based on Equations 2.13 and 2.18, ( )PDVar A  and ( )PAVar A  parabolically depend on 
( )PDE A  and ( )PAE A , respectively. In addition, ( )PAE A  should be proportional to ( )PDE A . In the 
experiment using lysed bovine blood, the result shows a clear parabolic relationship between 
( )PDVar A  and ( )PDE A  [Figure 2.15(a)]. The photon count fluctuation coefficient   was fitted to 
be 5.67%, close to the laser specification. The similar result between ( )PAVar A  and ( )PAE A  is 
shown in Figure 2.15(b). The coefficient   was fitted to be 5.76%, very close to the one for PD. 
In addition, Figure 2.15(c) shows that there is a good linearity between ( )PAE A  and ( )PDE A .  
 
Figure 2.16 Measurements for different photon count fluctuation coefficients. (a) For larger particle counts, the 
SNRPA at sufficiently high SNRth depends only on photon count fluctuation.  (b)-(d) If the particle count is small, the 
SNRPA at sufficiently high SNRth depends primarily on the particle count. (b) α = 0.0066. (c) α = 0.0284. (d) α = 
0.0587.  The dots are the measurement data, and the solid curves are the fitted results based on Equation 2.21. 
As mentioned above, we can regroup the laser pulses based on the photodiode readings. By doing 
this, the laser intensity fluctuation coefficient   can be artificially controlled to a predetermined 
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value. Figure 2.16(a) shows that with large particle counts, PASNR  is dominated by the light 
fluctuations when thSNR  increases, consistent with Equation 2.22. Here the neutral density filter 
was adjusted to change the laser fluence and thus to change the thSNR . On the other hand, when 
the particle counts are small in the detection volume, the measurement results with high thSNR  only 
rely on the particle counts [Figures. 2.16(b) to (d)], consistent with Equation 2.23. Although the 
photon count fluctuation coefficients are varied, the measurement results stay the same. Thus, the 
fluence-independent measurement is achieved with the conditions of high thSNR  and small particle 
counts. 
 
Figure 2.17 Quantitatively measuring particle concentration from different samples with the same light fluctuation. 
(a) The preset particle counts are 440 (purple), 220 (blue), 110 (red), 55 (green), and 27 (black). Solid lines: 
theoretical fitting based on Equation 2.23. (b) Measured particle count versus the preset value. 
Next, we applied our method to quantitatively measure five different particle concentration 
samples. Figure 2.17(a) shows measured results with five different preset particle counts of 440, 
220, 110, 55, and 27 in the detection volume. The experimental results agree well with the preset 
values. In addition, we observed that the measured particle count does not change with the laser 
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fluence any longer when the thSNR  is high enough. The fitted coefficient ( )pE N  in the model was 
used to quantify the absolute particle count for each sample. As shown in Figure 2.17(b), the 
experimental results agree well with the preset particle counts in the detection volume. 
We also measured RBCs to validate the feasibility of our method in biological applications. Figure 
2.18(a) illustrates the measured results with the fitting curve for four different preset RBC counts 
of 400, 300, 200, and 100 in the detection volume. We used the fitted coefficient ( )pE N  to 
represent the counts of RBCs and compared with the corresponding preset RBC counts [Figure 
2.18(b)]. The results demonstrate that our method is fluence-independent and can be used to 
quantitatively measure biological samples. 
For in vivo application, additional signal fluctuation mainly comes from the perturbation of laser 
fluence by micro-flows in the light path. To mimic the in vivo situation while maintaining the 
flexibility of varying the RBC concentration, we covered targets made of black tape and bovine-
blood-filled tubing with a living mouse ear, as shown in Figures 2.19 (a-c). 
 
Figure 2.18 Measured RBC counts under the same light fluctuation. (a) The preset particle counts are 400 (blue), 
300 (red), 200 (green), and 100 (black). Solid lines: theoretical fitting based on Equation 2.23. (b) Measured particle 
count versus the preset value. 
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We first measured the signal fluctuations from black tape, which did not show Brownian motion. 
As shown in Figure 2.19(d), measurements were made at 40 random spots on the black tape. For 
all the spots, the PA signal fluctuations were around 2%. As described before, the power-based 
signal-to-noise ratio (SNRPA) was used to denote the measured particle counts. Since a 2% 
fluctuation corresponds to an SNRPA of 4 × 10-4, it is negligible. The experimental results show 
that the in vivo PA signal fluctuation due to other sources rather than Brownian motion is 
insignificant. 
 
Figure 2.19 Measurement of RBC counts in tubing covered by a living mouse ear. (a) Photo of the experimental 
setup. (b) Close-up of the region within the red dashed box in (a), showing the blood-filled tubing and black-tape 
targets covered by the living mouse ear. (c) A typical cross-sectional PA image showing that the tubing and part of 
the black tape were covered by the mouse ear. (d) Measurement of PA amplitude fluctuation from black tape at 40 
random spots covered by the mouse ear. 
Furthermore, we measured RBC counts in the same setup. Figure 2.20(a) illustrates the measured 
results, with fitting curves for three different preset RBC counts of 1080, 540, and 270 in the 
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detection volume. We used the fitted coefficient E(Np) to represent the RBC counts. As shown in 
Figure 2.20(b), the experimental results agree with the preset RBC counts. The result shows that 
our method can be used to measure RBC counts in an in vivo mimicking situation using OR-PAM. 
To show the potential for actual in vivo applications of our method, we performed two more 
demonstrations, which correspond to anemia caused by blood loss and by RBC aggregation, 
respectively. In each in vivo experiment on RBC count, we maintained the laser fluence constant 
(see the Discussion section). In the first demonstration, saline was injected into mouse tail vein to 
mimic blood loss (blood dilution), as shown in Figure 2.21(a). The same vein was monitored to 
quantify the RBC count changes. Figure 2.21(b) shows a PA image of the vein, where the black 
cross denotes the monitoring spot. We slowly injected ~0.03 mL saline into the tail vein during a 
3 minute window. As shown in Figure 2.21(c-d), the measured RBC count was reduced by injected 
saline. As soon as we stopped injection, the RBC count quickly returned to its normal value. 
 
Figure 2.20 RBC count measurement with the blood-filled tubing covered by a mouse ear. (a) The preset RBC 
counts in the voxel were 1080 (red), 540 (green), and 270 (black). (b) Measured versus preset RBC counts. 
In the other demonstration, to induce RBC aggregation, we used ~0.3 mL 3% dextran-70 solution 
to mix with 3 mL original RBC solution. The diluted original and aggregated RBC solutions were 
 
 
0 4000 8000 12000
500
1000
1500
0
270
540
1080
270 540 1080SNRth
SNR
PA
Me
asu
red
 RB
C co
unt
Preset RBC count
(a) (b)
1080
540
270
810
810
ExperimentalIdeal
40  
imaged ex vivo by a commercial microscope, as shown in Figure 2.22. The results show that we 
can induce RBC aggregation successfully ex vivo and probably in vivo.  
 
Figure 2.21 In vivo RBC count changes in a mouse tail vein when injecting saline. (a) Animal setup in the 
experiment. The imaged area was downstream of the saline injection spot. (b) PA MAP image of part of the tail in 
vivo. The large vessel in the middle is the mouse tail vein where we injected the saline. The black cross denotes the 
monitoring spot. (c) Time course of PA amplitude. The red dashed box highlights a clear decrease in the PA signal 
mean value. (d) RBC counts measured by our method before, during, and after saline was injected into the tail vein. 
Then we performed an in vivo experiment to observe RBC aggregation. The same dextran-70 
solution was injected into a mouse through the tail vein, and the mouse ear was used to monitor 
the RBC aggregation, as shown in Figure 2.23(a). Figure 2.23(b) shows the PA image of the mouse 
ear, where the red cross denotes the RBC monitoring spot. As shown in Figure 2.23(c-d), an 
increase of PA signal fluctuation and corresponding RBC count decrease were observed about 50 
minutes after the dextran-70 solution injection. Based on the results of our ex vivo experiment, we 
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think that this decrease in RBC count was from RBC aggregation, induced by the mixing of 
dextran-70 solution with blood. 
 
Figure 2.22 RBC aggregation induced by 3% Dextran-70 solution. The concentration of RBCs was the same in the 
two images. (a) Original and (b) aggregated RBCs imaged by a commercial microscope. 
Discussion  Both the theoretical model and experimental study showed that our method is 
applicable when the particle count in the detection volume is sufficiently small such that the 
particle Brownian motion dominates the PA signal fluctuation. If we can control the photon count 
fluctuation coefficient within 1%, the maximum count of particles that we can measure is on the 
order of 1000 (≪ 1 ߙଶ⁄ ). By contrast, the minimum measurable count of particles is limited by 
thSNR . If the count of particles in the detection volume is too small, noise reduces the measuring 
accuracy significantly. Either particles with larger absorption cross-sections or greater detection 
volumes can reduce the minimum. Based on our experimental results (Figures 2.16(b)-(d)), we 
conclude that our method can measure as few as three RBCs in the detection volume. 
As shown in Figure 2.17, our measured particle counts are slightly larger than the preset absolute 
counts estimated based on the detection volume of 500 μm. This is most likely due to the inaccurate 
estimation of the detection volume. We calculated the detection volume based on the 1/e detection 
sensitivity field. However, particles not in this volume can still generate PA signals, which will 
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contribute to the total PA signals. If we take those particles into account, the actual detection 
volume becomes greater. 
 
Figure 2.23 RBC aggregation measured in vivo. (a) Animal mounting in the experiment. Dextran-70 solution was 
injected into the mouse through the tail vein. The mouse ear was imaged and monitored over time.  (b) PA MAP 
image of the mouse ear. The red cross denotes where we monitored the RBC count. (c) Time course of PA 
amplitude. The red dashed box highlights a clear increase in the PA signal fluctuation. (d) Time course of RBC 
count measured by our method. The selected red dashed box window highlights a decrease in RBC count. 
In addition, as shown in Figures. 2.16(a), 2.17(a), and 2.18(a), when thSNR  becomes high enough, 
the measured particle counts are independent of the thSNR  and laser fluence. Although we 
examined the complete trend in this study with varying thSNR , a measurement with a single, high 
enough thSNR  is sufficient to measure the fluence-independent particle counts in the detection 
volume, as we have done in the in vivo experiment.  
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In our experiments, we chose a flowing medium for the following two reasons. First, we focused 
on measuring counts of RBCs, which usually flow constantly in vivo. Second, using a flowing 
medium can avoid potential heat accumulation and photobleaching, which, however, can be 
mitigated by decreasing the pulse repetition rate. For example, the heat diffusion time is about 0.2 
ms in our experiment (characteristic dimension: 5 μm; thermal diffusivity: 1.3 × 10-3 cm2/s). Thus, 
a laser repetition rate of 1 kHz causes minimal heat accumulation, which is further reduced by 
blood perfusion. 
Finally, we may be able to apply our method in deep tissue imaging modalities such as acoustic 
resolution PAM and PA computed tomography where fluence compensation is even more 
challenging. However, compared with OR-PAM, their greater detection volume may require even 
lower particle concentrations. Although it may be difficult to detect absolute RBC counts, we can 
use our method to monitor the absolute counts of other cells in blood, such as intact or labeled 
white blood cells [72], which are much sparser in the blood stream. 
2.4 Conclusions  
First, we applied optical clearing to PAM. Our results show that both the penetration depth and 
lateral resolution of PA imaging can be enhanced by TOC. For backscattering-based optical 
imaging modalities such as optical coherence tomography, optical clearing can provide deeper 
penetration depth as well. However, it may destroy some of the intrinsic scattering contrasts that 
these modalities rely on, which can result in potential information loss. By contrast, PA imaging 
is based on optical absorption with 100% sensitivity. Since the optical absorption cross section of 
the substance (e.g., hemoglobin) remains largely intact in the optical clearing procedure, 
information loss is avoided. Not only can PA imaging benefit from optical clearing, it can also be 
44  
used to study the physiological effects induced by optical clearing. With enhanced penetration 
depth and resolution, PAM will become more valuable for structural, molecular, functional, and 
metabolic imaging. 
Second, we used PAM for quantitative mapping of bilirubin distribution. The RMSEP of 
concentration was quantified to be 0.52 mg/dL for pure bilirubin samples, 1.04 mg/dL for 
bilirubin-blood mixtures with 75% sO2, and 0.83 mg/dL for bilirubin-blood mixtures with 100% 
sO2, respectively. The bilirubin distribution, both in the pure bilirubin samples and in the blood-
mixed samples, was imaged by multi-wavelength PAM. Finally, imaging bilirubin with underlaid 
mouse skins illustrated that at least a 400 µm penetration depth can be achieved by PAM without 
noticeable degradation in accuracy. Therefore, our method shows promise to quantitatively image 
bilirubin in vivo for further clinical applications, such as the diagnosis of jaundice. 
Third, we used PAM for fluence-independent particle count measurement by statistically 
analyzing PA signals. This method has been experimentally verified by using different kinds of 
samples, including RBCs. We also demonstrated the feasibility of our method in the in vivo 
experiment. Therefore, our method shows promise for quantitatively measuring biological samples 
in vivo, which could be used for red blood cell aggregation monitoring.   
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Chapter 3 Pain Syndrome Study with Photoacoustic Tomography in Patients 
3.1 Microcirculatory Changes Identified by Photoacoustic Microscopy in Patients with Complex Regional Pain Syndrome Type I (CRPS-1) after Stellate Ganglion Blocks 
Background  Complex regional pain syndrome (CRPS) is a pain disorder characterized by severe 
and disproportionate pain, autonomic changes such as abnormal regulation of blood flow and 
sweating, edema of skin and subcutaneous tissues, motor disorders, and dystrophic changes.  The 
pathophysiological mechanism of CRPS is still poorly understood, although our knowledge of this 
syndrome has increased significantly [73-75]. Multiple factors, including vascular and 
microcirculatory dysfunction, neurogenic inflammation [76], alteration in sympathetic and 
catecholaminergic function, as well as peripheral and central sensitization, may all play important 
roles in the pathogenesis of this disabling syndrome [77]. However, microcirculatory parameters, 
including rate and volume of blood flow and tissue oxygen saturation (sO2), are of considerable 
interest for potentially diagnosing CRPS and monitoring its progress, due to the connection 
between the microvascular blood supply and the development of neuropathic pain [78].  
There is increasing evidence to show that inflammatory processes and immune reactions are 
involved in the pathophysiology of CRPS [79]. In a systemic review and meta-analysis study, 
Parkitny et al [76], concluded that CRPS is associated with proinflammatory states in the blood, 
blister fluids, and cerebrospinal fluid (CSF). The CRPS-related inflammation may change the 
sympathetic tone of blood vessels and therefore affect blood supply and tissue oxygenation.  The 
acute and chronic phases of CRPS demonstrate different inflammatory features in both clinical 
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manifestations and inflammatory profiles. The measurement of microcirculatory parameters, such 
as blood flow rate, blood volume, and blood oxygen saturation (sO2) can be used to potentially 
diagnose the presence of CRPS, to indicate the activity of the disease, and to monitor the 
effectiveness of the therapeutic intervention. 
In pain studies, traditional techniques for detecting microcirculatory parameters include functional 
magnetic resonance imaging (fMRI) and positron emission tomography (PET) [80]. However, 
both have limitations: fMRI makes indirect measurements by the blood-oxygenation-level 
dependent (BOLD) method [81, 82] or makes direct flow measurements with low sensitivity by 
the arterial spin labeling (ASL) method; PET has to use radioactive tracers to measure blood flow 
directly [83]. To overcome these limitations, optical methods provide alternative ways to make 
direct, sensitive, non-invasive, and non-ionizing measurements of blood flow and sO2 in pain 
studies [84-87]. Optical spectroscopic methods, such as near-infrared spectroscopy (NIRS) [84] 
and micro-lightguide spectrophotometry [85], can provide non-invasive measurement of average 
blood flow and sO2, but with poor spatial resolution. Optical coherence tomography and optical 
Doppler imaging provide blood vasculature anatomy imaging with high spatial resolution and 
sensitive measurements of flow speed, but lack high sensitivity for measuring sO2, because their 
imaging contrasts are based on optical scattering. 
The diagnosis of CRPS is based on clinical manifestations, and there are limited laboratory tests 
or image studies to verify the diagnosis. With its high spatial resolution and label-free nature, PAM 
is potentially an ideal tool for monitoring and diagnosing CRPS by imaging peripheral blood 
perfusion [88]. In this work, we performed a series of experiments to show the feasibility of this 
new imaging tool. 
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Methods  In this prospective observational study, we screened patients with a possible diagnosis 
of CRPS -1 who were referred to the Pain Management Center of Washington University in St. 
Louis between January 2011 and December 2011. Nine adult patients (28-69 years old, 6 female, 
3 male) with CRPS-1 were recruited. Patients with pain in only one upper extremity were selected 
to participate in the study. One patient withdrew from the study. Patients were considered to be 
candidates for the study if they were diagnosed with CRPS-1 by using the proposed new diagnostic 
criteria of the International Association for the Study of Pain (IASP) [89]. All patients signed 
consents to be involved in the study. All human research procedures were carried out in conformity 
with the protocol approved by the Institutional Review Board at Washington University in St. 
Louis. 
For all the patients, symptoms and signs of CRPS were present for less than one year. Average 
pain level was 5 or higher on a numerical rating score (NRS) scale of 0–10 (with 0 being no pain 
and 10 being the worst imaginable pain). Exclusion criteria were pregnancy, coagulopathy, fever, 
general infection or local infection at the block puncture site, substance abuse, peripheral 
neuropathy or any other diseases that may account for signs and symptoms mimicking CRPS.  
Benefits and risks of stellate ganglion block (SGB) were explained to the patients in detail. A 
written consent was obtained for the procedure. ASA standard monitors were applied during the 
procedure and post procedure in the recovery room. The skin temperature of the hands was 
measured before and 10 mins after the procedure. SGB on the cervical sympathetic chain was 
performed at the C7 vertebral level using the standard anterior paratracheal approach under 
fluoroscopic guidance. The patient was placed in the supine position with the head slightly 
hyperextended. The needle entry point was fluroscopically identified by anterior-posterior view at 
the junction of the C7 vertebral body and transverse process on the side of the diseased limb. Sterile 
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technique was used throughout the entire procedure. After sterilization and preparation, 1-3 ml of 
1% lidocaine was used for skin infiltration at needle entry point.  Then a 10-mm, 25-gauge nerve 
block needle was inserted and advanced to the junction of the transverse process and the 
corresponding C7 vertebral body. Bony contact was made. The appropriate needle positioning was 
confirmed by anterior-posterior and lateral views. Once the needle was confirmed in the correct 
position fluoroscopically, aspiration was made for negative blood and other body fluids. Then a 
small amount (0.5–1 ml) of contrast dye was injected to visualize and prevent potential 
intravascular injection. After an adequate craniocaudal contrast dye spread from C5 to T1 was 
obtained, an injection of 10 ml of 0.25% bupivacaine with 1:200,000 epinephrine was given in 2 
ml increments, with interval negative aspiration. The patient was observed in the recovery area for 
15 mins after the procedure. 10 mins after SGB, skin temperature in the block side increased 1.1 
± 0.1°C. Meanwhile, pain level reduced by 2.5 ± 0.6 on discharge.  
 
Figure 3.1 (a) Schematic of the OR-PAM and AR-PAM systems. AL: acoustic lens; CL: conical lens; DAQ: data 
acquisition system; M: mirror; UT: ultrasound transducer. (b) Photograph of the hand, showing the scanned regions. 
a: region scanned by AR-PAM; b: region scanned by OR-PAM. 
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The experimental paradigm consisted of two imaging sessions, with a SGB between the sessions. 
For each patient, the back of their hand and the cuticle of the same hand were imaged before SGB 
(baseline) and then after SGB. Two sites (Figure 3.1b) were chosen to image: superficial 
microvasculature at the cuticle and deeper and larger vessels at the back of the hand.  
According to its light illumination mechanism, PAM can be classified into two categories: AR-
PAM and OR-PAM. In AR-PAM, the light is weakly focused, and the lateral resolution is 
determined by the acoustic focusing of the ultrasonic transducer. In OR-PAM, the light is tightly 
focused, and thus the lateral resolution is determined by the optical focusing provided by the 
objective. The axial resolution of both AR- and OR-PAM is determined by the bandwidth of the 
transducer used in the system. Usually optical focusing is much tighter than acoustic focusing, and 
thus OR-PAM has a better lateral resolution than AR-PAM. However, since acoustic scattering is 
much weaker than optical scattering in soft tissue, AR-PAM can focus deeper than OR-PAM. To 
monitor hemodynamic changes with both high spatial resolution and deep penetration, both AR- 
and OR-PAM systems were used in this research. The schematics are shown in Figure 3.1(a). In 
the AR-PAM system, a donut-shaped illumination is formed when light passes through the conical 
lens. A 20-MHz ultrasonic transducer collects the PA signals. In the OR-PAM system, light 
illumination and acoustic collection are achieved by an ultrasound-optical beam combiner. A 50-
MHz ultrasonic transducer detects the PA signals. Each laser pulse generates a one-dimensional 
depth-resolved image (“A-line”) in both the AR- and OR-PAM systems. By two-dimensional 
raster-scanning of the entire area, a three-dimensional image can be acquired. For more accurate 
sO2 calculation in both AR- and OR-PAM systems, a photodiode compensates for the local fluence 
fluctuation. A detailed system description can be found in our previous papers. The lateral 
resolutions of the AR- and OR-PAM systems are 80 µm and 3 µm, respectively. To measure sO2, 
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light at two wavelengths, 570 nm and 578 nm, was used in both AR- and OR-PAM. The PA signal 
from both wavelengths can be described as 
  2 21 1 1( ) ( ( ) ( ) )Hb Hb HbO HbOP k C C           (3.1) 
  2 22 2 2( ) ( ( ) ( ) )Hb Hb HbO HbOP k C C       ,    (3.2) 
where P denotes PA signal amplitude, λ1 and λ2 denote the first and second wavelengths, k denotes 
a system dependent constant, ɛ denotes the molar extinction coefficient, Hb denotes deoxygenated 
hemoglobin, HbO2 denotes the oxygenated hemoglobin, and C denotes the molar concentration. 
Based on Equations 3.1 and 3.2, we can solve for CHb and CHbO2. In the end, sO2 can be calculated 
as 
    2
2
2 HbOHbO Hb
CsO C C  .      (3.3) 
 
Figure 3.2 Maximum amplitude projection (MAP) images of vasculature in the back of one patient’s hand by AR-
PAM. MAP image in the depth range between 0.4 mm and 0.7 mm before block (a) and after block (b). MAP image 
in the depth range between 0.7 mm and 1 mm before block (c) and after block (d). NPA, normalized photoacoustic 
amplitude. 
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Results  Typical AR- and OR-PAM hand images of patients are shown in Figures 3.2 and 3.3, 
respectively. For fair comparisons, the distance between the patient’s hand and the ultrasonic 
transducer was adjusted to be the same before and after SGB for imaging. In AR-PAM, a ~6 mm 
by 6 mm field of view was scanned. The signals down to 1 mm deep were collected. Due to the 
high axial resolution of AR-PAM, we were able to differentiate signals from different depths. 
Maximum-amplitude-projection (MAP) images along the depth direction, with ranges of 0.4 mm-
0.7 mm and 0.7 mm-1.0 mm, are shown in Figure 3.2. Two major differences can be easily seen: 
more blood vessels and stronger signals after the block. Because the local optical fluence 
fluctuation had been compensated for, the PA signal was mainly dependent on the absorption 
coefficient of the target. Thus, an increase in the PA signal indicates an increase in the local 
absorption coefficient, probably due to increased blood concentration or volume. Therefore, we 
suspect that there was increasing blood perfusion and blood vessel dilation after the block.  
 
Figure 3.3 OR-PAM vasculature image of the fingertip of one patient. MAP of scanned region before block (a) and 
after block (b).  The dashed box represents the region used for statistical analysis. (c) Close-up image of the 
capillary loop indicated by the arrow in (b). 
Typical blood vessels in the finger cuticle imaged by OR-PAM are shown in Figure 3.3. As 
indicated in Figures 3.3(b) and (c), OR-PAM successfully imaged a single capillary loop, which 
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is the smallest vessel in human blood circulation. As shown in Figure 3.3(b), a stronger signal was 
found after the block, which is consistent with the results from AR-PAM. 
 
Figure 3.4 (a) Normalized photoacoustic (PA) signal measured by AR-PAM before and after block in different depth 
ranges. (b) Average sO2 measured by AR-PAM before and after block. (c) Normalized PA signal measured by OR-
PAM before and after block. 
Statistical analysis of all the patient data are shown in Figure 3.4. Figure 3.4(a) shows the average 
increase in signal intensity at different depths after the block. On average, there was more than 
50% signal increase in all depth ranges. In addition, the signal increased most within the 0.1 mm 
– 0.4 mm depth range, where the capillary bed is located. Similar results from OR-PAM can be 
found in Figure 3.4(c). According to the dual-wavelength measurement by AR-PAM, the average 
sO2 increased ~4%.  
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Discussion  CRPS-1 is a difficult clinical condition to diagnose and treat. Early diagnosis and 
management are necessary to prevent a long-standing or permanent disability. The diagnosis of 
CRPS-1 is primarily based on clinical observation and assessment of symptoms and signs, 
although a diagnostic algorithm has been recently proposed [90]. A unique pathophysiological 
mechanism for CRPS-I has not yet been established and therefore sensitive and specific laboratory 
diagnostic parameters are lacking, resulting in difficulties in making valid diagnosis and 
distinguishing CRPS from other extremity pain entities. Several diagnostic procedures, such as 
bone scintigraphy, plain radiographs, quantitative sensory testing, skin temperature measurements, 
and fMRI are used to support the diagnosis of CRPS. However, they require pathognomonic 
markers. For example, the recommended three phase bone scan demonstrated both cortical and 
cancellous osteopenia in CRPS patients and controls treated with casting [85]. Meanwhile, there 
are no universally accepted tools to measure the effectiveness of treatment.  It is known that CRPS 
is accompanied by impaired microcirculation of affected tissue, such as vasoconstriction and 
reduced regional blood flow and oxygenation, which then leads to skin temperature change, pain, 
and atrophic changes. Thus, a direct non-invasive measurement of microcirculation is of 
considerable interest for accurate and early diagnosis of CRPS. PAM is shown to be a powerful 
tool for studying the microcirculatory system at the site of CRPS. In the presented results, the 
blood perfusion increase after SGB was directly observed, which is consistent with the patients’ 
subjective sense of pain relief. Based on time-of-flight in the depth direction and raster 2D 
scanning in the horizontal direction, PAM can reconstruct 3D information of the blood vessel 
anatomy and the distributions of hemoglobin concentration and oxygen saturation, which may 
provide additional information for diagnosis and improvement after treatment. Our experiments 
show that a relatively obvious blood perfusion increase after SGB exists at the shallow depth where 
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the capillary bed is located. Although the data are preliminary, they suggest a strong relation 
between the development of CRPS and microcirculatory changes.  
PAM is able to measure the oxygen saturation in a single blood vessel or the average values in a 
desired area. Pain, autonomic changes, and functioning impairment in patients with CRPS may be 
more related to the actual tissue extraction of oxygen and nutrients in the affected area than to the 
supply of oxygen and nutrients from microcirculation. Some reports suggest that arterial oxygen 
saturation (SaO2) alone may not be helpful enough to diagnose CRPS, and thus venous oxygen 
saturation is essential. Due to its absorption contrast mechanism, PAM with double wavelengths 
is sensitive to both oxyhemoglobin and deoxyhemoglobin, and is able to measure the oxygen 
saturation in both arteries and veins. 
SGB with local anesthetics is used frequently in the management of CRPS-1 of the upper 
extremities, with variable degrees of success in pain relief and improvement of function. This 
inconsistency of outcome may be related to sympathetically maintained pain (SMP) and 
sympathetically independent pain (SIP).  SMP may be differentiated from SIP by a sympatholytic 
challenge provided by an intravenous injection of the α-adrenergic blocker phentolamine or 
sympathetic blocks. Our preliminary data indicated only a subset of patients responded to SGB 
well, with significant pain relief and changes of PA signal and sO2, which supports the observation 
that “neuropathic pain is mediated or maintained by the sympathetic nervous system in only a 
subset of patients”. 
Despite the advantages listed above, the two-dimensional scanning of current PAM has relatively 
a long acquisition time, which leads to some motion artifacts in the image. Further improvement 
of imaging speed is possible by implementing mirror scanning. Limited by the strong attenuation 
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of high frequency acoustic signals, the AR-PAM system used in this work can image only as deep 
as 3 mm in biological tissue. To investigate the microcirculatory changes of deep tissue such as 
muscles and bones in the area affected by CRPS, an AR-PAM system with a lower central 
frequency transducer (e.g., 5 MHz) can be used in the future, which extends the imaging depth to 
4 cm. Based on a small number of subjects, our data are promising but preliminary. Randomized, 
controlled, and double-blinded clinical trials are needed to verify the clinical application of PAM 
systems to CRPS evaluation and management.  
3.2 Conclusions 
In this paper, peripheral blood vessels in two sites in patients’ hands were imaged by PAM systems. 
From pre to post SGB block, there were a 50% increase in signal intensity of PAM and 4% increase 
in sO2, which agreed with the increased temperature and decreased pain level. The results showed 
that blood perfusion increased after SBG, which is consistent with prior reports. Unlike other 
imaging methods, PAM can provide non-invasive high spatial resolution images as well as 
functional sO2 measurement. In these preliminary results, PAM showed its potential for helping 
both monitor and diagnose CRPS. 
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Chapter 4 Photoacoustic Flowmetry in Humans 
In this chapter, we aim to quantify blood flow velocity in humans. We first propose a cross-
correlation-based method to measure blood flow velocity by using optical resolution photoacoustic 
microscopy. We demonstrate our method in phantom, ex vivo, and in vivo experiments. However, 
because this method can work only in the optical ballistic regime, deep flow in humans cannot be 
quantified. Then we propose two methods to solve this problem: saline-injection-based and 
cuffing-based flowmetry. For the saline-injection-based method, we demonstrated it in mice. For 
the cuffing-based method, we successfully measured blood flow speed in humans. Work in this 
chapter has been published in Journal of Biomedical Optics, Optics Letters, and Journal of 
Biophotonics [31, 91-93]. 
4.1 Calibration-free Transverse Blood Flow Measurement Based on Time-domain Cross Correlation Using Photoacoustic Microscopy in Vivo 
Background  Noninvasive and accurate blood flow measurement provides important 
physiological information for medical diagnosis [94, 95]. Many imaging modalities have been 
implemented to measure blood flow [96-100]. PAM has been widely used in various applications, 
including functional brain imaging, gene expression, and early cancer detection. PAM has also 
shown promising results in flow measurement [30, 101-105]. These previous investigations were 
based on photoacoustic Doppler (PAD) shift, time-domain PA autocorrelation or frequency-
domain PAD bandwidth broadening. The PAD shift is introduced when a static ultrasonic 
transducer receives PA signals generated by moving particles. The shift can be converted to flow 
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velocity using the Doppler theory. This method has several advantages, such as illumination angle 
independence, high signal-to-noise ratio (SNR), and weak background noise. However, Doppler 
flowmetry becomes less accurate when the detection axis becomes nearly perpendicular to the 
flow direction. Therefore, it cannot accurately measure microvascular flow velocity at a shallow 
depth where the transverse flow component dominates. Time-domain PA autocorrelation can also 
be used for flow velocity measurement. When a moving particle traverses the illumination area, 
the flow velocity is determined by the time duration of the resultant PA signal and can be extracted 
by analyzing the slope of the normalized autocorrelation function. In the frequency domain, flow 
velocity is represented by the broadening effect of the PAD bandwidth. However, the measured 
flow velocity from these methods depends on the particle size, and a calibration is required.   
 
Figure 4.1 Principle of flow measurement by PAM based on cross correlation. (a) Two laser beams (blue and red 
arrows) illuminate the measurement area of a blood vessel alternately. The axes of the two beams are separated by 
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distance L. Sequential A-lines are acquired at (b) Av and (c) Bv at an interval time of 2tp. (d) The slow-time PA 
profiles from Av and Bv are shifted in time by t . 
In this section, we propose a method to measure transverse flow velocity by using cross correlation. 
The proposed method overcomes the limitations of previous approaches. We shall demonstrate 
that our proposed method is able to deliver a pair of spatially-resolved laser beams to the target, 
so that the transverse flow speed and the direction can be directly retrieved by cross correlating a 
pair of slow-time PA profiles (to be defined below). In addition, our method can detect depth-
dependent flow velocity, and the measurement is not affected by the particle size. Moreover, we 
investigated both maximum and minimum measurable velocities. Finally, we demonstrate the 
feasibility of our method in phantom, ex vivo, and in vivo experiments. 
Method  The principle of cross-correlation-based flow velocity measurement is depicted in Figure 
4.1. Two parallel laser beams, separated in space by a distance L, alternately illuminate the 
measurement region of a blood vessel. The time interval between two consecutive laser pulses is 
tp. The flow is assumed to be laminar and linear. An in-plane streamline with a velocity v  is drawn 
as a green arrow in Figure 4.1(a). The points of intersection between the two beams and the 
streamline are denoted as Av and Bv. Both points lie within the acoustic focus of the ultrasonic 
transducer. Radiofrequency PA A-lines, referred to as “fast-time-resolved” PA signals, are 
acquired from each beam alternately at half of the pulse repetition rate of the laser (Figure 4.1(b), 
(c)). A series of fast-time-resolved signals is time-gated according to the depths of Av and Bv. PA 
amplitudes of all A-lines at these depths are extracted by taking the maximum amplitude projection 
(MAP) of the A-lines. Subsequently, a series of PA amplitudes from A-line sequences acquired 
from both points are converted to two envelopes, referred to as “slow-time” PA profiles. When the 
same group of particles traverses Av and Bv, the slow-time PA profiles from Av and Bv appear with 
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identical shapes, and with a time shift t  (Figure 4.1(d)). The time shift is computed with the cross 
correlation of the slow-time PA profiles from Av and Bv. The flow velocity is calculated by  
v  Lsinq t  t p  ,        (4.1) 
where q  is the angle of the particle flow direction with respect to the detection (z) axis. In addition, 
the flow direction can be determined from the sign of t . Therefore, both flow speed and direction 
are measured by the cross-correlation method. Moreover, flow velocity at any selected depth can 
be measured. 
 
Figure 4.2 Schematic overview of the setup, not to scale. AMP, signal amplifiers and filters; DAQ, data acquisition; 
DMD, digital micromirror device; IP, Intermediate image plane; L1-L3, lenses (focal lengths f1-f3); M1-M2, mirrors; 
OL, objective lens; UT, ultrasound transducer. 
Two requirements are imposed by the proposed method. First, the voxel size should be small 
enough that the PA signal fluctuation induced by the variations of the particle density within the 
voxel is greater than the noise. Second, two spatially separated laser beams must be delivered at a 
high repetition rate, in order to enable measuring a fast flow velocity. We integrated a digital 
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micromirror device (DMD) (.7XGA DDR Discovery™ 4100, Texas Instruments) with an OR-
PAM system to satisfy these two requirements (Figure 4.2). A diode-pumped solid-state laser 
(INNOSLAB, Edgewave, 532 nm  ) with a repetition rate of 10 kHz ( 0.1 mspt  ) was used as 
the illumination source. This laser had maximum output pulse energy of 300 µJ, and the pulse 
duration was 10 ns. After spatial filtering and collimation, the expanded laser beam was incident 
on the DMD. Patterns generated by micromirrors on the DMD were imaged into the target. An 
ultrasonic transducer (V214-BB-RM, Olympus NDT Panametrics) with a central frequency of 50 
MHz was placed confocally with the objective lens. Fast-time-resolved PA signals (A-lines) were 
amplified and then acquired by a 12-bit digitizer (ATS9350, AlazarTech). The entire system was 
synchronized by a multifunction data acquisition card (PCI-6251, National Instruments). 
The DMD consists of an array of 1024×768 micromirrors with a pitch distance of 13.68 µm. To 
realize the “ON” or “OFF” state, each micromirror can be latched in either the +12° or -12° 
position from the DMD surface normal. The entire device, therefore, functions as a binary-
amplitude spatial light modulator. As the most widely adopted spatial light modulator, DMD has 
advantages in operation speed, stability, and reliability. Two binary patterns were encoded on the 
DMD in our experiments. For the first pattern, a 96×96 micromirror square was turned “ON” while 
the rest of micromirrors stayed “OFF”. The second pattern had the identical square pattern but was 
spatially shifted along the flow direction by a set distance. For most experiments presented in this 
paper, this distance was chosen to be 2.63 mm. When alternately imaged into the target, these two 
patterns formed two laser beams. Each beam had a diameter of 5 µm, and the separation between 
these beams was 10 µm. The DMD was synchronized with the laser at a rate of 10 kHz, resulting 
in an A-line repetition rate of 5 kHz (interval time 0.2 ms) from each beam. 
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We measured the flow of microspheres in a straight capillary tubing (60985-700, inner diameter = 
300 µm, VWR). Three sizes of microspheres (17137-15 (diameter µm 3 = pd ), 15714-5 (
µm 6 = pd ), and 24294-2 ( µm 10 = pd ), Polysciences) were separately suspended in water. The 
suspensions were pumped into the tubing through a syringe, and the flow speed was controlled by 
a syringe pump (BSP-99M, Braintree Scientific). For each measurement, totalN  pulses were used 
for each laser beam to acquire a series of PA A-lines at a 5 kHz rate for a given detection time 
ttotal  2Ntotalt p . For a selected fast-time window, we applied maximum amplitude projection 
(MAP) to all measured A-lines to detect the slow-time PA profile, then correlated the two slow-
time PA profiles and averaged the multiple correlation results to determine the flow velocity.  
Results  In the first experiment, we used 10-µm-diameter microspheres to measure the flow 
velocity (Figure 4.3). The red line with the legend of “Ideal” in this and the following figures 
represents measured flow velocities equal to the preset values. The flow velocity was varied from 
-6.84 mm/s to +6.84 mm/s, which covers the normal physiological flow velocity range in arterioles 
with diameters less than 80 µm. The tubing was adjusted to be perpendicular to the detection axis 
of the ultrasound transducer ( 90q   ), and to be in the same plane as the two laser beams. For 
each measurement, we observed an expected positive or negative time shift from the raw data 
(insets in Figure 4.3). The average velocity and standard error at each data point were computed 
from 10 measurements. The measured velocities agreed well with the preset average flow speeds 
in both directions. We used the root-mean-square error of prediction (RMSEP) to describe the 
measurement accuracy,   
2 2( ) s rRMSEP v e e  ,     (4.2) 
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where systematic error se and random error re are defined as 
es  1n1 (vmi  vpi )2i1
n      (4.3) 
and   
er  1n s i2i1
n .      (4.4) 
Here, piv , vmi , and s i are the preset average velocity, measured average velocity, and measured 
standard error of the ith velocity out of a total of n velocities, respectively. For this experiment, the 
RMSEP of the measured flow velocity was quantified to be 0.22 mm/s, with the systematic error 
and random error being 0.10 mm/s and 0.19 mm/s, respectively. 
 
Figure 4.3 Measured transverse flow velocities using 10-µm-diameter microspheres. Inset figures show raw slow-
time PA profiles from Av (blue) and Bv (red) in Figure 4.1 at two selected flow velocities v = +6.14 mm/s and v = –
6.14 mm/s. Error bars: standard errors. 
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In addition, we investigated the flow velocity with different particle sizes (Figure 4.4). 
Experimental results evidently illustrate that the measured flow velocity is independent of the 
particle size (Figure 4.4(a)) within the preset range 0.55 6.49 mm/sv   . A detailed examination of 
the raw data (Figures 4.4(b)-(d)) reveals that measured slow-time PA profiles were modulated with 
different intensities and time durations, which resulted both from different particle sizes and from 
the relative positions between the particles and the laser beams. For the autocorrelation method, 
because the flow velocity is calculated based on the time-domain narrowing effect (or on 
bandwidth broadening in the frequency domain) of individual profiles, it is necessary to calibrate 
for the particle size.  On the contrary, we circumvented this calibration process by analyzing the 
time delay between two sequential slow-time PA profiles. Consequently, all three sets of raw data 
produced the consistent result, and the flow velocity was not subject to experimental changes in 
particle sizes.  
 
Figure 4.4 (a) Flow velocities measured using three sizes of microspheres. (b)-(d) The slow-time PA profiles from 
Av (blue solid line) and Bv (red dashed line) in Figure 4.1 with the same flow speed (dashed box in (a)) for (b) 3 μm, 
(c) 6 μm, and (d) 10 μm -diameter microspheres. The calculated average time shift between the blue and red slow-
time PA profiles is the same regardless of individual profile shapes. 
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The size-independent flow measurement makes the proposed method attractive for measuring 
blood flow. The non-spherical shape of red blood cells (RBCs) or RBC clusters would alter the 
shape of the slow-time PA profiles. Using previous methods, this change would increase the 
measurement errors. On the other hand, using the proposed method, flow velocity information is 
extracted from the time delay between the two slow-time PA profiles. Because the two laser beams 
are only 5-15 µm away from each other, RBCs or RBC clusters are likely to maintain their 
orientation when they traverse these two laser beams. Thus, the two slow-time PA profiles will 
still have identical shapes, and the flow speed can be accurately calculated.  
 
Figure 4.5 Measured flow velocities with parabolic fits in the depth direction, using 10-µm-diameter microspheres. 
The peak flow velocities are 2.25 mm/s (●) and 4.67 mm/s (■). 
With the assumption of laminar flow, the transverse flow velocity should follow a parabolic curve 
in the depth direction. In our experiment, each PA A-line was time gated with 10 ns windows, 
which divided the entire tubing diameter uniformly into 20 streamlines of 15 µm thick each. Then 
the flow velocity was analyzed for each layer. Two measured depth profiles for different preset 
average transverse flow velocities are shown with parabolic fits in Figure 4.5. Measured peak 
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velocities of these two profiles are 2.25 mm/s and 4.67 mm/s. As expected, the flow velocity peaks 
at the center of the tubing and falls approximately parabolically to the wall.  
Using the proposed method, we further investigated the maximum and minimum measurable flow 
velocities of 10-µm-diameter microspheres. For the measurement of maximum flow velocity, the 
experimental results illustrated that the measured values were linear with the preset flow velocities 
until plateaus develop appreciably (Figure 4.6(a)). In theory, the maximum measurable velocity 
was reached when a flowing particle was detected only once by each laser beam. Thus, the 
maximum measurable velocity in our experimental setup at 90q    can be computed by Equation 
4.1 as 
pt
Lv max .                                                               (4.5) 
Equation 4.5 shows that, at a constant laser repetition rate, maxv solely depends on the distance L . 
For 5,  10,  and 15 µmL  , the theoretical maxv  values are 50.00 mm/s, 100.00 mm/s, and 150.00 
mm/s, respectively. In comparison, the maximum relative errors of the measurements occurred at 
preset velocities of 26.73, 50.47, and 56.41 mm/s in the range of mm/s 34.6246.0 v  (Figure 
4.6(b)). This discrepancy comes from the discrete nature of the time shift measurement, which 
produces the plateaus before the theoretical maxv  values. Based on Equation 4.1 ( 90q   in our 
experimental setup), we could not accurately measure velocities between ( )pL t t   and 
( 3 )pL t t  . The velocity difference   is expressed as 
2| | 3 ( )( 3 )pp p p p
LtL L
t t t t t t t t           .                                           (4.6) 
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Figure 4.6 Quantification of the maximum measurable velocities for 10-µm-diameter microspheres. (a) Log-log plot 
of the measured flow velocities for three different distances. (b) Semi-log plot of the relative errors of the measured 
velocities. 
The mean velocity   within this velocity range is: 
( 2 )( ) / 23 ( )( 3 )pp p p p
L t tL L
t t t t t t t t
           .                                           (4.7) 
Thus, the maximum relative error is given by  
2
2p p
tv
v t t
    .                    (4.8) 
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Equation 4.8 shows that, when t  had small discrete values, the cross-correlation process had low 
accuracy, resulting in the plateaus in Figure 4.6(a). In order to maintain acceptable velocity 
accuracy, we chose a 2-point shift between the two slow-time PA profiles to calculate maxv , which 
has a relative error less than 33%. The resulting maxv  values were 10.00 mm/s for 5 µmL  , 20.00 
mm/s for 10 µmL  , and 30.00 mm/s for 15 µmL  .  
It is noted that a short distance between the two beams (L) and a long detection time ( totalt ) are 
conducive to slow flow measurement. Fundamentally, the minimum measurable velocity minv  is 
limited by particle diffusion caused by Brownian motion. Particles could move out of the laser 
illumination area in a laminar flow during the traveling time, which would de-correlate the slow-
time PA profiles from Av and Bv. Based on the Brownian motion theory, the average displacement 
of particles r with diameter pd can be calculated by 
p
Bd
Tk
t
r 2
2 ,              (9) 
where vLt  , Bk is Boltzmann’s constant, η is the viscosity of the liquid, and T is the absolute 
temperature. Given a Gaussian beam with 5 µm diameter, a 1 μm shift in space introduces only a 
small change of PA signals, and the two slow-time PA profiles are still correlated. 
Correspondingly, we can detect flow with velocity as low as min 1.44 μm/sv   for 10-μm-diameter 
particles.  
In addition, particles can drift in the depth direction due to gravity, drag, or convective motion due 
to laser-induced temperature distribution. Such depth drift could lead to de-correlation between 
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slow-time PA profiles for a chosen fast-time gate. The following example is given to estimate the 
minimum measurable flow velocity. Particles with 10 µm diameter are suspended in water. Let us 
assume a 5% mismatch between the mass densities of the particle and the surrounding liquid, due 
to either the material or thermal expansion of the particle. Such a level of mismatch is typical for 
red blood cells in phosphate buffered saline especially in the presence of a substantial temperature 
fluctuation. The particles mainly experience the Stokes force, buoyance, and the gravity force. In 
equilibrium, these particles carry a flow speed of 2.72 µm/s in the depth direction. Assuming the 
particle starts drifting from a depth in the center of a 10 ns window, it would take 2.76 s for the 
particle to drift out of the time window. Correspondingly, minv  would be approximately 1.80 µm/s 
for a distance 5 μmL  .  
Before this limit would be reached, however, other experimental factors might intervene in the 
measurement. Flow velocity, especially in biological systems, changes over time. Hence, there is 
a good reason to keep the detection time as short as possible. In our experiments, at a slow velocity, 
it was possible that the particle had not traversed the laser beam during the entire measurement; as 
a result, only a fraction of the slow-time PA profile of the particle was captured. Consequently, 
the cross-correlation result was exacerbated due to reduced correlation between the two measured 
slow-time PA profiles. Thus, we required that the full profile of the particle be captured by both 
laser beams to maintain an accurate cross-correlation result, which defined minv . Correspondingly, 
minv was determined by the distance L, beam diameter bd , particle size pd , total time for one 
measurement ( ttotal ), and the noise-induced correlation peak shift nN , using 
vmin  db  L d p[2(Ntotal Nn )1]t p .     (2.10) 
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The typical SNR in our experiments ranged from 15 to 20, and our results showed that this 
produced only a negligible nN in the measurement; therefore, minv was primarily determined by 
the distance parameter and totalt .  
We first set the distance to three different numbers ( 5,  10,  and 15 µmL  ) to examine minv  (Figure 
4.7(a)). We measured flows in the range 0.06 – 0.46 mm/sv   at these distances. The calculated 
minv  for these distances were 0.20 mm/s, 0.25 mm/s, and 0.30 mm/s, respectively, for a fixed time
100 mstotalt  . Above the calculated minv , the measured results were in close agreement with the 
preset values. However, when the preset flow velocities were smaller than the calculated minv , the 
measured velocities stayed roughly equal to the calculated minv .  
   
Figure 4.7 Quantification of the minimum measurable flow velocity for 10-µm-diameter microspheres. (a) Measured 
flow velocities for three different distances at slow preset flow velocity range 0.06 0.46 mm/sv    for a fixed 
time 100 mstotalt  . (b) Measured flow velocities using three different totalt  at a fixed distance 5 µmL  . 
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We also studied the relation between totalt  and minv  at a fixed distance 5 µmL   (Figure 4.7(b)). 
Measurements in the range 0.06 –1.34 mm/sv   were made using 25, 50, and 100 mstotalt  . The 
calculated minv  for these times were 0.80 mm/s, 0.40 mm/s, and 0.20 mm/s, respectively. Similar 
to Figure 4.7(a), the measured flow velocity reached a constant value approximately equal to the 
calculated minv , showing good agreement with the theoretical values.    
Next, we demonstrated the feasibility of our proposed method in a biological environment. A piece 
of chicken tissue 250–300 µm thick was placed underneath the tubing as a scattering and absorbing 
medium. We set the distance μm 10L  for the experiment and used 10-µm-diameter microspheres 
as the target. As shown in Figure 4.8, the measured flow velocities were in conformity with preset 
values in the entire range. From Equations 4.2–4.4, the measurement accuracy was calculated to 
be 0.35 mm/s, with a systematic error of 0.29 mm/s and a random error of 0.19 mm/s. 
 
Figure 4.8 Measured average flow velocities with underlaid chicken tissue. Error bars: standard errors. 
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In an ex-vivo study, fresh defibrinated bovine blood (910-250, Quad Five) was driven through a straight 
plastic tube (60985-700, inner diameter = 300 μm, VWR) by a syringe pump (BSP-99M, Braintree 
Scientific), with flow velocities ranging from 0.45 to 18 mm/s. In the experiment, the distance d between 
the two measurement spots Av and Bv was set to 5 μm, and the angle θ was set to 90°. The standard deviation 
at each data point was calculated from 10 measurements. As shown in Figure 4.9, the measured flow 
velocities agreed well with the preset values in the flow velocity range. The similar shape of the slow-time 
PA amplitude profiles in each of the two inset figures clearly illustrates that the same group of RBCs was 
accurately captured at Av and Bv. The unequal PA amplitudes from Av and Bv are due to the uneven spatial 
light intensity distribution and uneven detection sensitivity of the transducer in the field of view. Because 
Δt must be an integral multiple of the laser pulse interval, the cross-correlation process had low precision 
when Δt digitally approached zero, displaying as larger error bars in Figure 4.9.  
 
Figure 4.9 Measured transverse flow velocities of defibrinated bovine blood versus preset values. Inset figures show time 
courses of slow-time PA profiles from Av (red line) and Bv (black dashed line) in (a) at two selected flow velocities, v = 2.25 
mm/s and v = 13.5 mm/s. 
We next measured flow velocities of vessels in a mouse ear in vivo. A nude mouse (Hsd:Athymic, Nude 
Mouse; Harlan, Indianapolis, Indiana) was used in the experiment. The experimental animal procedure was 
carried out in conformance with the laboratory animal protocols approved by the Animal Studies 
Committee of Washington University in St. Louis. For all the in vivo experiments, we targeted shallow 
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micro-vascular structures that were parallel to the tissue surface. As a result, all the measured vessels were 
perpendicular to the detection axis (θ = 90°).    
 
Figure 4.10  In vivo blood flow measurements in vessels with different structures. Black crosses denote locations of the two 
measurement spots. Red arrows denote the flow direction. PA images of (a) a loop vessel, (b) a straight vessel, and (c) a vessel 
bifurcation. (d-f) Time courses of slow-time PA profiles from Av and Bv in (a-c), respectively. 
Table 4.1 Flow velocity measurements in vessels with different structures. 
 
To show that our method can be used to measure flow velocity in vessels with different structures, we 
imaged three representative structures: a loop, a straight vessel, and a bifurcation, as shown in Figures 
4.10(a-c). To quantify the flow velocities in these vessels, two close spots Av and Bv were selected in each 
vessel. The measured slow-time PA amplitude profiles from Av and Bv in Figures 4.10(a-c) are shown in 
Figures 4.10(d-f), respectively. The measured distances d, time shifts Δt, and flow velocities v are shown 
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in Table 4.1. In addition, the signs of the time shift Δt in each vessel denote the flow direction of the blood, 
as marked by the red arrows in Figures 4.10(a-c). Our results show that, in vessels with different structures, 
the flow velocity can be quantified by our method.  
 
Figure 4.11 Measurement of flow changes in a curved vessel. (a) PA image of the vessel. Black crosses denote the locations of 
the monitoring spots. Red arrow denotes the flow direction. Time courses of slow-time PA profiles from (b) Av1 and Bv1, (c) Av2 
and Bv2 in (a). 
Table 4.2 Flow velocity measurements in a single vessel. 
 
In addition, we studied spatial flow velocity changes in the same vessel. As shown in Figure 4.11(a), two 
pairs of spots denoted as Av1-Bv1, Av2-Bv2, were chosen to measure flow velocities in different locations 
of a curved vessel. The measured slow-time PA amplitude profiles from Av1-Bv1 and Av2-Bv2 are shown 
in Figure 4.11(b-c), respectively. As shown in Table 4.2, the flow velocities calculated from Av1-Bv1 and 
Av2-Bv2 were 0.24 mm/s and 0.14 mm/s, respectively. The similar profiles from Av1, Bv1, Av2, and Bv2 
illustrate that the same group of RBCs was imaged at these spots. However, while travelling in the vessel, 
this group of RBCs slowed down. This might be caused by blood leakage, blood flux conservation, or 
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interaction between RBCs and the vessel wall. To our knowledge, this is the first time that a flow velocity 
change was observed for the same group of RBCs, which might be useful for many blood disorder 
studies. 
 
Figure 4.12 Observation of feature conservation in a vessel bifurcation. (a) PA image of a vessel bifurcation. Black crosses 
denote locations of the monitoring spots. Red arrows denote the flow directions. Time courses of slow-time PA profiles from (b) 
Av1 and Bv1, (c) Av2 and Bv2, (d) Av3 and Bv3 in (a). The duration of the valley was (b) t1, (c) t2, and (d) t3. 
Table 4.3 Flow velocity measurements in a vessel bifurcation. 
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Finally, we further quantified the flow velocity from the same feature in a vessel bifurcation. A PA image 
of the vessel bifurcation is shown in Figure 4.12(a). For flow measurement, three pairs of spots (Av1-Bv1, 
Av2-Bv2, and Av3-Bv3) were chosen in the bifurcation. The measured slow-time PA amplitude profiles from 
Av1-Bv1, Av2-Bv2, and Av3-Bv3 are shown in Figure 4.12(b-d), respectively. The measured distances d, time 
shifts Δt, and flow velocities v are shown in Table 4.3. Because of the conservation of blood flux in the 
vessel, the features appearing upstream should be also observed downstream. If the cross section of the 
feature keeps constant in the stream, which might be true over a very short distance, the length of the 
features should be the same. As shown in Figure 4.12(b-d), the same “valley” was observed in all three 
pairs. The time durations of this valley in all the three figures were quantified to be t1 = 262.2 ms, t2 = 277.8 
ms, and t3 = 272.4 ms, respectively. Thus, the valley in the upstream vessel had a length of t1 × v1 = 186.2 
μm. Meanwhile, the sum of the valley lengths in the two downstream vessels was calculated to be t2 × v2 + 
t3 × v3 = 170.9 μm, close to the valley length in the upstream vessel. Taken together, these observations 
supported the idea of blood flux conservation. 
4.2 Saline-injection-based Photoacoustic Flowmetry in the Optical Diffusive Regime 
Background  PAT is a modality that provides imaging in either two dimensions (2D) or three 
dimensions (3D). Combining the advantages of optical excitation and acoustic detection, PAT can 
image rich optical absorption contrast in biological tissues at depths. To date, PAT has been widely 
used for both structural and functional biological imaging in many different fields, including 
hematology, oncology, dermatology, ophthalmology, and gastroenterology. Depending on the 
limiting factor for spatial resolution, PAT can be divided into optical-resolution PAT (OR-PAT) 
and acoustic-resolution PAT (AR-PAT). In OR-PAT, the optical focus is much tighter than the 
acoustic focus, and a high spatial resolution can be achieved. AR-PAT provides a lower spatial 
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resolution, defined by the acoustic focus. Nevertheless, because in biological tissue ultrasound 
suffers much less scattering than light, AR-PAT can achieve deep imaging with a depth-to-
resolution ratio of more than 100. So far, with high resolution, OR-PAT has imaged a variety of 
important biological parameters in vivo, such as sO2, blood flow velocity, pulse wave velocity, and 
the metabolic rate of oxygen (MRO2). However, although AR-PAT has imaged sO2 at depths, it 
still cannot provide in vivo blood flow information. In addition, in order to calculate MRO2 with 
PAT, flow needs to be measured, which makes it even more important to quantify flow. 
There are two fundamental reasons why it is difficult for AR-PAT to measure blood flow velocity. 
First, unlike ultrasound, PAT almost has no speckles [106]. If the target has a smooth boundary 
with respect to the wavelengths of the PA waves, the boundary signals of the target will stand out, 
while the speckles inside the target are largely suppressed. Because blood vessels in biological 
tissues usually have smooth boundaries, it is challenging for PAT to extract blood flow information 
merely based on speckle fluctuations. Second, AR-PAT has a lower spatial resolution than OR-
PAT and thus a larger detection voxel size. In typical OR-PAT, the spatial resolution is comparable 
to the size of red blood cells (RBCs). Thus, when RBCs flow into and out of the detection voxel, 
the PA signal changes are observable. By monitoring how fast the signal changes, the flow velocity 
can be calculated. However, in AR-PAT, the large detection voxel contains many more RBCs than 
in OR-PAT. Because the number of RBCs inside the detection voxel can be assumed to follow a 
Poisson distribution [27], a larger mean number of RBCs leads to a smaller relative RBC number 
change and thus a smaller PA signal change. For example, if there are 10,000 RBCs in the detection 
voxel, the PA signal change due to the RBC number change would be only around 1%, so the 
system would need a signal-to-noise ratio (SNR) of more than 100 to measure the flow velocity.  
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Although challenging, different methods have been proposed to achieve blood flow measurement 
with AR-PAT, including PA Doppler (PAD) flowmetry and ultrasonically encoded PA flowgraphy 
(UE-PAF). Based on the PAD effect, different PAD shifts have been observed from particles 
moving with different flow speeds, and the Doppler theory allows the flow speeds to be calculated. 
However, to observe the PAD shift, the moving particles have to be very sparse. Thus, this method 
cannot measure the flow velocity of whole blood. But by using ultrasound to encode the PA 
signals, UE-PAF can achieve whole blood flow imaging in deep tissue [107]. In UE-PAF, 
modulated ultrasound is focused into the blood vessel to create a heating source. Because PA 
signals are proportional to temperature, the PA signals from the heated area will increase. By 
monitoring the increased PA signals along the blood vessel, the flow speed in the blood vessel can 
be measured. However, this method’s complexity has limited it to only phantoms, and so far, no 
in vivo data have been reported. 
 
Figure 4.13 Schematic of the photoacoustic tomography system (a) and saline injection (b). (a) FB, fiber bundle; FC, 
fiber coupler; OPO, optical parametric oscillator. (b) d was 15 cm in the phantom experiment. 
In this section, we present a new method to measure blood flow velocity deep in biological tissues.  
To increase the PA signal changes due to flowing RBCs, saline is injected into the blood stream. 
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As a result, at the saline-blood interfaces, the PA signals have sharp changes ― blood’s PA signal 
is strong while saline’s signal is negligibly low. Thus, by monitoring the time course of the PA 
signals from the interface, the flow velocity in the blood stream can be quantified. In addition, 
because saline is widely used for intravenous infusion, no extra saline injection is needed in such 
patients.  
 
Figure 4.14 Steps to extract the flow velocity. (a) Time course of the photoacoustic (PA) amplitude of the blood 
vessel in the phantom experiment. (b) Blue dots, one dimensional PA amplitude along the dashed line in (a); Red 
line, error function fitting; Black arrow, the mean value of the error function. The mean value represents the saline-
blood-interface (SBI). (c) Blue circles, time course of the SBIs; Red line, linear fitting. 
Material and Method  We employed a typical AR-PAT system to demonstrate this idea. As 
shown in Figure 4.13(a), the light source was a tunable optical parametric oscillator laser with a 
repetition rate of 20 Hz. For deep tissue imaging, 680 nm light was chosen for the experiments. 
The light was first coupled into an optical fiber bundle, which was divided into two rectangular 
strips (20 mm × 1.25 mm) at the output end. The incident pulse fluence on the tissue surface was 
controlled to be around 10 mJ/cm2, which was less than the safety limit set by the American 
National Standards Institute (20 mJ/cm2) at this wavelength. A linear-array transducer containing 
256 elements (LZ250, Visualsonics Inc.) was used to detect the PA signals. Thus, each laser pulse 
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generated a two-dimensional (2D) PA image. With a central frequency around 21 MHz and a 78% 
one-way bandwidth, this transducer array had an axial resolution of 86 μm. With a size of 23 mm 
× 3 mm and a cylindrical focus at 15 mm, this transducer array provided a lateral resolution of 119 
μm and an elevational resolution of 1237 μm. 
Figure 4.13(b) shows a schematic of saline injection in phantom experiments. A silicone tube (300 
μm inner diameter) filled with blood was used to mimic the blood vessel. The blood was pumped 
into the tube through a syringe, and the flow speed was controlled by a syringe pump. A second 
syringe was employed to perpendicularly inject saline solution into the tube. The distance between 
the injection point and the center of the field of view was set to 15 cm so the injection disturbance 
to the flow was minimized. 
 
Figure 4.15 Phantom experiments. Time course of the photoacoustic (PA) amplitude of the blood with flow velocity 
at 0.2 (a), 1.3 (b), and 4.5 mm/s (c) in a vessel. (d) Measured flow velocity versus preset flow velocity. Red circles, 
experimental measurement; Blue line, ideal fit if the measured and preset velocities are identical. 
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The flow velocity was extracted in three steps from the PA signals of the saline-blood interface 
(SBI). First, the whole process of the interface propagation through the field of view (FOV) of the 
transducer array was monitored. At each time point, a 2D image of the blood vessel was acquired 
and then converted to a one dimensional (1D) amplitude image via the Hilbert transformation, 
followed by taking the absolute value and then taking the peak amplitude. By piecing together all 
the 1D images at consecutive time points, a final 2D amplitude image of the SBI was achieved, as 
shown in Figure 4.14(a). Note that the x-axis is the displacement along the blood vessel and the y-
axis is time. Second, at each time point, the 1D PA amplitude of the phantom blood vessel was 
fitted by an error function to extract the location of the SBI, as indicated by the mean value of the 
error function in Figure 4.14(b). Last, by tracking the SBI along the phantom blood vessel, we 
calculated the blood stream flow velocity. As shown in Figure 4.14(c), although only two 
measurements of the SBI sufficed to calculate the blood flow velocity, multiple measurements 
could improve the accuracy by linear fitting. 
Results  Phantom experiments were first performed to demonstrate the capability of our method 
in flow measurement. To confirm that our method can measure blood flow in biological tissue at 
depths of the optical diffusive regime, fresh chicken breast tissue with a thickness of ~2 mm was 
laid atop the phantom blood vessel. Figures 4.15(a-c) show three representative 2D amplitude 
images of the SBI, with blood stream flow velocities of 0.2, 1.3, and 4.5 mm/s. Because of the 
strong optical absorption difference between blood and saline, SBIs were imaged by PAT with 
high contrast, as shown in Figures 4.15(a-c). Thus, by linear fittings of the SBI spatial-temporal 
locations, our measured blood flow velocities agreed well with the preset values, as shown in 
Figure 4.15(d). The root-mean-square error of prediction (RMSEP) was calculated to be 0.29 
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mm/s, indicating that our method can measure deep blood flow with high accuracy. Thus, we 
concluded that our method should be able to measure blood flow velocity in vivo. 
 
Figure 4.16 In vivo experiments. Photoacoustic (PA) images of the tail vein before saline injection (a) and after 
saline injection (b). Dashed lines indicate the vessel region. (c) Time course of the PA amplitude of the tail vein 
when the saline flushed in. 
We then measured blood flow velocity in a mouse tail vein in vivo to show the detection ability of 
the saline-injection-based method. Again, a slice of chicken breast tissue (~1 mm) was put atop 
the tail vein to increase the measurement depth. Saline was injected into the tail vein with a home-
made catheter to induce the SBI for blood flow measurement. The distance between the injection 
spot and the imaging window was ~3 cm. During the experiment, an infrared lamp kept the mouse 
warm, and a breathing anesthesia system (E–Z Anesthesia, Euthanex) kept the mouse motionless. 
All experimental animal procedures were carried out in conformity with laboratory animal 
protocols approved by the Animal Studies Committee of Washington University in St. Louis. As 
shown in Figure 4.16(a), before saline injection, the whole tail vein in the field of view (FOV) 
could be clearly observed. However, when the saline flushed in, there were almost no signals from 
the blood vessel anymore because of the low absorption of saline, as shown in Figure 4.16(b). 
Again, the SBI’s spatial-temporal location can be clearly imaged by PAT, as shown in Figure 
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4.16(c). Based on the same procedure as in the phantom experiments, the blood flow velocity was 
quantified to be around 4.5 mm/s.  
Discussions  With an ~10 mm FOV along the lateral direction, the system has a frame rate of 10 
Hz. Limited by the system’s memory, a maximum of 1000 continuous frames can be stored. If we 
use the lateral resolution (119 μm) as the minimum displacement that the system can separate, the 
minimum flow speed the system can measure is around 119 μm/50 s = 2.38 μm/s. For the 
maximum flow speed, in theory it should be around 50 mm/s based on the current frame rate and 
FOV along the lateral direction. Here we require that the saline-blood interface be imaged twice 
in order to measure the flow speed, for both the minimum and maximum flow estimation. 
4.3 Cuffing-based Photoacoustic Flowmetry in Humans in Depths of the Optical Diffusive Regime 
Background  In this section, we present a cuffing-based method to measure blood flow speed in 
humans. Aided by a common sphygmomanometer, PAT successfully measured blood flow in 
humans for the first time. This procedure has three steps. First, a window along the blood vessel 
of interest is imaged. Second, the blood flow upstream of the window is stopped by cuffing the 
blood vessel with the sphygmomanometer. A high pressure (220 mg Hg in our experiments) is 
maintained in the cuff for a short time (e.g., 10 seconds) until there is almost no blood left in the 
vessel in the imaging window. Finally, the sphygmomanometer is quickly released, and the blood 
flow speed is calculated by monitoring the blood wash-in process. 
Methods  To test our method, we employed a commercialized linear-array-transducer based PAT 
system (Vevo LAZR, VisualSonics, Toronto, ON, Canada), as shown in Figure 4.17(a-b). A 
Nd:YAG laser combined with an optical parameter oscillator provided tunable illumination 
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wavelengths from 680 nm to 970 nm. To achieve deep penetration, 850 nm was chosen for our 
experiments. The laser pulse had a width around 10 ns and a repetition rate of 20 Hz. The light 
was coupled to an optical fiber bundle that was divided into two rectangular fiber bundles (20 mm 
× 1.25 mm) with an illumination angle of 60° toward the tissue surface. The incident pulse fluence 
was around 5 mJ/cm2, below the safety limit set by the American National Standards Institute for 
this wavelength. A 256-element linear-array-transducer, with a central frequency of around 21 
MHz (one-way bandwidth, 78%) and a size of 20 mm × 3 mm, detected ultrasonic signals. The 
array and the fiber bundles were aligned coaxially and confocally to maximize the system’s 
sensitivity. Because the data acquisition system contained only 64 channels, a 4:1 electronic 
multiplexer was used to acquire ultrasonic signals from all the transducer elements. Thus, with a 
20 Hz laser, the two-dimensional frame rate was reduced to 5 Hz to obtain a full-width image. 
However, the frame rate could be increased up to 20 Hz with fewer receiving channels and thus a 
smaller field of view (FOV). In our experiments, a frame rate of 10 Hz was used with a FOV of 
about 12 mm × 10 mm, along the axial and lateral directions of the array, respectively. 
 
Figure 4.17 Photographs of the PAT system (a) and the linear-array-transducer (b). The workstation has a 64-
channel data acquisition system, a data processing system, and an image display interface. (c) A schematic of the 
array in the phantom experiments. 
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We first conducted phantom experiments to demonstrate the feasibility of our method for 
measuring blood flow speed in the diffusive regime. As shown in Figure 4.17(c), to mimic a deeply 
embedded blood vessel, silicone tubing with an inner diameter of 300 μm (11-189-15E, Fisher 
Scientific, Houston, TX) was overlaid by a piece of chicken breast tissue with a 2 mm thickness. 
Fresh bovine blood (910, QUAD FIVE INC., Ryegate, MT) was flowed inside the tubing at 
different speeds controlled by a syringe pump (BSP-99M, Braintree Scientific, Braintree, MA).  
 
Figure 4.18 Phantom experiments. PA signal amplitude versus lateral position x and time t measured at different 
preset flow speeds: (a) 0.14 mm/s and (b) 1.1 mm/s. (c) Time course of the blood fronts in (a) and (b), where the 
slope of each linear fit directly represents the flow speed. (d) Log-log plot of the measured flow speeds versus the 
preset values. (e) Semi-log plot of the relative errors of the measured speeds in (d). 
As shown in Figures 4.18(a)-(b), the blood wash-in process at different flow speeds could be 
accurately imaged. In those images, each column represents the one-dimensional PA amplitude 
image of the tubing in the FOV at a given time point. With increasing time, more blood flowed 
into the tubing in the imaging window. By quantifying how fast the blood front moved, the flow 
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speed could be calculated, as shown in Figure 4.18(c). As shown in Figure 4.18(d), the measured 
flow speed agreed well with the preset values. The measured minimum flow speed was 0.035 
mm/s, which is smaller than the typical blood flow speed in capillaries in humans and also slower 
than the lowest flow speed that Doppler US can measure, i.e., 1 mm/s. We also tested the maximum 
measurable flow speed. To measure the moving speed of the blood front, we have to at least image 
it twice. Thus, based on current frame rate (10 Hz) and FOV (10 mm along the tubing direction), 
in theory our maximum measurable flow speed should be around 50 mm/s. However, as shown in 
Figure 4.18(e), as the preset flow speed increased, the measurement error increased as well, which 
was probably due to the decreased number of times that the blood front was imaged. In our 
experiment, the maximum measured flow speed was around 42 mm/s. 
 
Figure 4.19 Photographs of the human experiments with imaging sites at a forearm radial artery (a), an index finger 
radial artery (b), and a forearm radial vein (c). 
Results  We then performed human experiments to show the capability of our method for 
measuring blood flow speed in vivo. As shown in Figure 4.19, there were three different imaging 
sites in our human experiments — a radial artery in the right forearm, a radial artery in the index 
finger of the right hand, and a radial vein in the right forearm. As shown in Figures. 4.19(a) and 
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(b), the upper arm was cuffed by the sphygmomanometer to measure the blood flow speed in the 
radial arteries in the forearm and finger. To measure venous flow speed, instead of cuffing, we 
directly compressed the radial vein close to the wrist and monitored a downstream location of the 
same vein, as shown in Figure 4.19(c). All methods and experimental procedures were carried out 
in accordance with the guidelines of The Institutional Review Board of Washington University in 
St. Louis. All experimental protocols were approved by The Institutional Review Board of 
Washington University in St. Louis. 
 
Figure 4.20 Human experiments. Representative PA images of a forearm radial artery (a), an index finger radial 
artery (b), and a forearm radial vein (c) before cuffing, during cuffing, and after releasing. The yellow dashed lines 
indicate the blood vessel regions. 
As shown in Figures 4.20(a)-(c), the cuffing and releasing processes for all tested locations were 
clearly imaged. Before cuffing the vessel, both the top and bottom walls of the vessel could be 
detected. After cuffing, the blood vessel almost completely disappeared in the PA images. Once 
the cuff was released, the blood vessel appeared again. The recovery speed depended on the blood 
flow speed: For the big artery, the recovery process was the fastest; while for the vein, the process 
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was the slowest. Based on the same procedure as in the phantom experiments, the flow speeds in 
these blood vessels were calculated to be around 44 mm/s (forearm radial artery), 20 mm/s (index 
finger radial artery), and 10 mm/s (forearm radial vein). The measured blood flow speeds were 
close to the flow speeds measured with US Doppler, which were 50 mm/s, 18 mm/s, and 9.3 mm/s, 
respectively. Based on the experimental results, we conclude that our cuffing-based PA method 
can measure blood flow in humans in both big and small blood vessels. 
Discussion  When the blood vessel is completely cuffed, there is almost no detectable blood in the 
downstream but blood accumulates under pressure upstream of the cuffing spot. Thus, the initial 
post-release blood wash-in process is a surge, which diminishes to normal flow with increased 
distance from the cuffing spot. In our measurements, we sought to avoid surge effects by setting 
the downstream imaging locations at ~ 5 cm for the vein flow measurement and more than 30 cm 
for arterial measurements. 
4.4 Conclusions 
First, we provided a cross-correlation-based method to measure flow velocity in vivo by using PAM. 
Different from previous flow measurement methods, this method was independent of particle size. Thus, a 
calibration-free absolute flow velocity can be measured, including both the flow speed and direction. 
Taking advantage of absolute flow velocity information, we observed accurate flow velocity changes and 
the feature conservation nature in the vessel. With more accurate flow information, our method provides a 
promising tool for more accurate measurement of the metabolic rate of oxygen, and for blood disorder 
studies. 
Second, to our knowledge, for the first time we achieved deep blood flow measurement in vivo 
with AR-PAT. SBIs were created by injecting saline into the blood vessel, and the blood flow 
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velocity was measured by monitoring a single SBI propagation in the blood stream. Our phantom 
experiments showed that we could achieve a highly accurate measurement of blood flow velocity 
in deep biological tissue, with a RMSEP of 0.29 mm/s. The in vivo mouse experiments indicated 
that we could potentially measure blood flow in humans. Based on saline injection, our method is 
particularly suitable for blood flow quantification in patients already undergoing intravenous 
infusion.  
At last, for the first time to our knowledge, we measured blood flow speed in humans with PAT. 
By cuffing and releasing the targeted blood vessels, the flow information could be extracted. In 
phantom experiments, the minimum and maximum measurable flow speeds with the current 
system were experimentally quantified to be around 0.035 mm/s and 42 mm/s, respectively. We 
further applied our method to measure both arterial and venous flow speeds in humans. Because 
we used a handheld photoacoustic probe, our method can easily be used to detect blood flow speed 
both in the clinic and at home. 
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Chapter 5 Photoacoustic Tomography of Human Brain Vasculature 
In this chapter, we image brains both in mice and humans. In the first section, we imaged the whole 
mouse brain with two systems: a ring transducer array with center frequency of 5 MHz and a linear 
array with 21 MHz center frequency. In the second section, we build a circular scan system with a 
0.5 MHz center frequency for human brain imaging.  
5.1 Photoacoustic Tomography of Mouse Brain in Vivo 
Methods  We first used a cylindrical-view PACT system for brain imaging. The system contained 
a 512-element full ring transducer array with a ring diameter of 25 cm. Each transducer element 
had a center frequency of 5 MHz and a 90% (one-way) detection bandwidth. To improve the cross-
sectional imaging ability, each element was cylindrically focused to reject out-of-plane signals. 
The combined foci from all elements provided a central imaging region with an ~20 mm diameter 
and ~1 mm thickness. Strictly speaking, such a system is a circular-view system, since only a ring, 
not a cylinder, is used to reconstruct the image. However, by taking advantage of its cylindrical 
focusing capability, high-quality 2D cross sectional images are attainable. In addition, by scanning 
the sample or the array along the elevational direction, 3D images can be acquired. Within the 
imaging region, the system provided 125-250 µm transverse resolution in the circumferential 
direction and 1250 µm axial resolution in the radial direction. A laser operating at 1064 nm was 
used for illumination. An acoustic reflector was used to reflect ultrasound signals from the mouse 
brain to the transducer array. 
We next used a 256-element linear-array-transducer, with a central frequency of around 21 MHz 
(one-way bandwidth, 78%) and a size of 20 mm × 3 mm, for brain imaging. Because the data 
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acquisition system contained only 64 channels, a 4:1 electronic multiplexer was used to acquire 
ultrasonic signals from all the transducer elements. Thus, with a 20 Hz laser at 1064 nm, the two-
dimensional frame rate was reduced to 5 Hz to obtain a full-width image. In addition, we rotated 
the linear array from -40° to 40° to increase the acceptance angle for mouse brain imaging. 
 
Figure 5.1  PACT of a mouse brain with a 5 MHz transducer array at two coronal planes. 
Results  As shown in Figure 5.1, a mouse brain could be imaged at two different coronal planes. 
Signature vessels can be detected, such as diving vessels, the superior sagittal sinus, and the 
posterior cerebral artery. In addition, the bottom of the mouse brain can also be imaged.  However, 
because this system had poor spatial resolutions, the image contrast was not very high. One way 
to improve the image contrast is to employ a high frequency transducer array with a better 
elevational resolution. Thus, we next implemented a transducer array with 21 MHz center 
frequency. With this system, more blood vessels could be resolved with higher contrast, as shown 
in Figure 5.2.  
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Figure 5.2  Blood vasculature imaged by a 21 MHz transducer array. 
5.2 Photoacoustic Tomography of the Human Brain in Vivo 
Background  Current human brain imaging modalities include positron emission tomography 
(PET), functional magnetic resonance imaging (fMRI), diffuse optical tomography (DOT), and 
ultrasonography. However, all of them have limitations. PET requires tracers for sufficient 
contrast, which involves exposure to ionizing radiation. fMRI detects water and only indirectly 
measures brain functions, so the relationship between fMRI signals and underlying brain activities 
still remains unclear. In addition, both PET and fMRI employ nonportable imaging equipment and 
are very expensive. As a pure optical imaging modality, DOT suffers from a very low spatial 
resolution because of the strong optical scattering in both the skin and skull. Ultrasonography does 
not have the optical scattering problem, but suffers strong attenuation and distortion from the skull. 
Thus it can image only the pediatric brain before the closure of fontanelles. Moreover, the imaging 
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contrast of ultrasonography is based on acoustic scattering, which is low in soft brain tissue. 
Collectively, a complementary brain imaging modality is still desired. 
Combining the advantages of optical excitation and acoustic detection, PAT is a promising 
alternative brain imaging tool. Compared to the brain imaging modalities listed above, PAT has 
four advantages: (1) Its contrast is based on intrinsic optical absorption, so it does not require 
ionizing radiation. (2) It detects the rich optical absorption contrast of biological tissue (such as 
hemoglobin, lipid, and DNA), and thus can perform both structural and functional imaging. (3) 
Because acoustic scattering is much lower than optical scattering in biological tissue, PAT can 
maintain a high resolution in deep tissue. (4) Although PAT also suffers acoustic attenuation and 
distortion due to the skull, it has only a one-way problem, unlike ultrasonography.  
Previously, we reported that both a graphite phantom and a canine brain were imaged by PAT 
through a human skull. In that work, many artifacts appeared, which significantly reduced the 
image quality of the target. In reality, besides the targeted brain vessels, which are below the skull, 
there are also blood vessels above the skull (e.g., the vessels in the scalp). In the following text, 
for simplification, we use superficial blood vessels (SBVs) and cortical blood vessels (CBVs) to 
represent the blood vessels above and below the skull. It is estimated that PA signals generated 
from SBVs are at least 50 times stronger than those from CBVs, due to light attenuation. If we 
take into account the strong acoustic attenuation of the skull, the final detected signals of SBVs 
would be more than 100 times stronger than those of CBVs, even if we use, for example, a 
transducer with a center frequency at 0.5 MHz. How to mitigate those unwanted but strong 
superficial signals becomes a big roadblock for human brain imaging. 
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In this section, we introduce an acoustic blocker to remove the interfering signals generated from 
the SBVs. We show that, with the acoustic blocker, the CBVs below the skull can be imaged with 
almost no interference from the skull and the SBVs. In addition, skin from a monkey’s head and a 
piece of chicken breast tissue were used to mimic real human head skin and the attached tissues. 
We show that the CBVs can be recovered, even with the thick tissue, skin, and SBVs. Our 
experimental results suggest that PAT can be used as a potential human brain imaging modality. 
 
Figure 5.3 Schematic of human brain imaging system. 
Methods  A system schematic is shown in Figure 5.3. A Q-switched Nd: YAG laser (PRO-350-
10, Newport, Irvine, CA) operating at 1064 nm was the light source. The laser pulse had a pulse 
width of 6.5 ns and a repetition rate of 10 Hz. After being expanded by a concave lens (LC2679-
C, Thorlabs, Newton, NJ) and homogenized by a ground glass diffuser (DG10-1500, Thorlabs, 
Newton, NJ), the laser pulses finally illuminated the target. Latex cords (1775T21, McMaster-
Carr, Elmhurst, IL) were used as the test targets. Some of them were placed above the human skull 
(Skull Unlimited International Inc. Oklahoma City, OK), mimicking the SBVs, while the others 
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were below the skull, mimicking the CBVs. The optical fluence at the skull surface was estimated 
to be 36 mJ/cm2, which was smaller than the American National Standard Institute (ANSI) limit 
(100 mJ/cm2). A 0.5 MHz ultrasonic transducer (V318-SU, Olympus, Waltham, MA) with a 
bandwidth of 70% detected the signals. The transducer was mounted on a rotation plate, which 
was driven by a step motor. Signals at 400 angles were detected by the transducer, amplified by 
an amplifier, and finally directed to a data-acquisition (DAQ) card (ATS9462-001-USD, 
ALAZAR TECHNOLOGIES INC., Pointe-Claire, CANADA). The transducer, skull, and 
phantoms were all immersed in water, which was contained in a home-made tank with O-rings for 
water sealing. 
 
Figure 5.4 Cortex blood vessel (CBV) phantom experiment. (a) Photograph of the latex rubber phantom to mimic 
CBVs. (b) PACT image of the pure phantom. (c) Photograph of the skull with phantom inside. (d) PACT image of 
the phantom with skull. (e) Photograph of the acoustic blocker. (f) PACT image of the phantom with skull with the 
acoustic blocker. The dashed circles in (d) highlight the artifacts removed by the acoustic blocker, as shown in (f). 
Scale bars: 1 cm. 
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As shown in Figure 5.3, a styrofoam cup was used an acoustic blocker to reduce the interfering 
signals from the SBVs. The bottom of the cup was cut off for light transmission. Since the 
styrofoam contains a myriad of air cavities, it acts mainly as an acoustic reflector. Thus, by 
properly positioning the acoustic blocker, most of the interfering signals from the SBVs were 
reflected by the cup, while the signals from CBVs were unaffected. Ultimately, the transducer 
received very few interfering signals but most of the targeted signals, and a much cleaner image 
of the CBVs was achieved. 
 
Figure 5.5 Superficial blood vessels (SBV) phantom experiment. (a) Photograph of the skull with SBVs. (b) PACT 
image of the SBV. (c) PACT image of the CBVs inside the skull with SBVs with the acoustic blocker. Scale bars: 1 
cm. 
Results  Figure 5.4(a) shows a photograph of the CBVs phantom used in the experiment. The 
diameter of the latex rubber is 1.5 mm. We first acquired a control image without putting the 
phantom below the skull, as shown in Figure 5.4(b). Based on Figure 5.4(b), we can see the whole 
phantom can be successfully detected, and there is no distortion in the reconstructed image. 
However, after adding the skull (Figure 5.4(c)), three obvious differences can be observed in the 
reconstructed image (Figure 5.4(d)). First, many artifacts (e.g., artifacts inside the green-dotted 
oval) appeared. Second, the whole image became distorted, which can be clearly observed, 
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especially in the red-dashed oval area. Third, the image intensity was much less homogenous. The 
intensity in some parts of the phantom is much stronger than in other parts, and some parts of the 
phantom have almost disappeared in the image. Although these three differences are all caused by 
the skull, they have different origins. The first difference, the strong artifacts, stems from the light 
absorption of the skull. As mentioned above, the skull decreases the signals from the CBVs more 
than 100 times. Thus, in order to maintain a similar signal-to-noise (SNR) in Figure 5.4(d) as in 
Figure 5.4(b), incident pulses with much higher energy were applied (e.g., 100 times). Thus, 
although the absorption coefficient of the skull at 1064 nm is very small, the specific optical energy 
deposition can be high, and so can the PA signals. The distortion and inhomogeneity problems, 
the last two differences, are both mainly caused by the acoustic heterogeneity of the skull, which 
affects the local speed of sound, scattering, and absorption. In addition, the interfering signals can 
also cause inhomogeneity. Figure 5.4(e) shows the acoustic blocker used in our experiments. The 
acoustic blocker was squeezed tightly against the skull to reduce possible gaps. Figure 5.4(f) shows 
the reconstructed image after implementing the acoustic blocker. Compared to Figure 5.4(d), the 
artifacts are significantly reduced.  
As shown in Figure 5.4(d), even with only the skull, the image quality is significantly reduced. 
However, in reality, there are always some SBVs above the skull, which will worsen the already 
bad situation. To mimic the SBVs, we pasted a latex rubber cross on the skull, as shown in Figure 
5.5(a). As expected, we could detect only the SBVs without using an acoustic blocker (Figure 
5.5(b)), because of the strong optical and acoustic attenuation of the skull. However, after we added 
the same acoustic blocker as in the first experiment, the SBVs almost completely disappeared in 
the image, and the targeted CBVs showed up again. Compared to Figure 5.4(f), although the whole 
phantom can also be clearly identified in Figure 5.5(c), the image quality is lower in Figure 5.5(c), 
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and the artifacts are stronger. Our results show that with the presence of both the SBVs and CBVs, 
PAT can still get a very good image of the CBVs. 
 
Figure 5.6 Phantom experiment with SBVs, chicken tissue, and monkey skin. (a) Schematic of the complicated 
phantom. (b) Photograph of the phantom. (c) PACT image of the CBVs with only SBVs and monkey skin. (c) 
PACT image of the CBVs with SBVs, chicken tissue, and monkey skin. Scale bars: 1 cm. 
To further mimic a real human head, we added monkey skin and a piece of chicken breast tissue 
on top of the skull, as shown in Figure 5.6(a). The SBVs were still there, between the chicken 
tissue and the skull. The monkey skin was 1.5 mm thick, and the chicken tissue was 5 mm thick, 
very similar to the thicknesses of the human skin and scalp. The human skull was measured by X-
ray CT, and its thickness was about 4 mm at the top. Thus, the total sample thickness above the 
CBVs was about 10.5 mm. Figure 5.6(b) shows images of the monkey skin, chicken tissue, and 
the human skull. Step by step, we first imaged the phantoms with only the monkey skin (i.e., 
without the chicken tissue), as shown in Figure 5.6(c). The whole “CBVs” are still very clearly in 
the image. As shown Figure 5.6(d), the whole CBVs still can be identified, although the contrast 
is much lower. 
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5.3 Conclusions 
In this chapter, we successfully imaged a whole mouse brain. Many representative blood vessels 
could be detected, as well as the deepest portion of the brain. We also built a system for human 
brain imaging. With an acoustic blocker, the SBVs’ signals could be successfully removed in the 
phantom experiments.  
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Chapter 6 Photoacoustic Imaging of Melanoma in Patients 
In this chapter, we aim to image melanoma and measure melanoma depth in patients. We first 
developed handheld PAM to detect melanoma and determine tumor depth in nude mice in vivo. 
Compared to our previous PAM system for melanoma imaging, a new light delivery mechanism 
is introduced to improve light penetration. We show that melanomas with 4.1 mm and 3.7 mm 
thicknesses can be successfully detected in phantom and in in vivo experiments, respectively. To 
solve the imaging speed problem, we then applied a linear-array-based photoacoustic probe to 
detect melanin-containing melanoma tumor depth and volume in nude mice in vivo. This system 
can image melanomas at five frames per second (fps), which is much faster than our previous 
handheld single transducer system (0.1 fps). We first theoretically show that, in addition to the 
higher frame rate, almost the entire boundary of the melanoma can be detected by the linear-array-
based probe, while only the horizontal boundary could be detected by the previous system. Then 
we demonstrate the ability of this linear-array-based system in measuring both the depth and 
volume of melanoma through phantom, ex vivo, and in vivo experiments. The volume detection 
ability also enables us to accurately calculate the rate of growth of the tumor, which is an important 
parameter in quantifying the tumor activity. In the end, we applied this linear array probe to image 
melanoma and quantify melanoma depth in patients. Work in this chapter has been published in 
Optics Letters and Journal of Biophotonics [108, 109]. 
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6.1 Handheld Photoacoustic Microscopy to Detect Melanoma Depth in Vivo 
Background  Melanoma is a malignant tumor of melanocytes. It is now the fifth most common cancer in 
the United States [110, 111], where there were about 76,690 men and women diagnosed with melanoma 
in 2013 alone. Although melanoma accounts for less than 5% of all skin cancers, it causes more than 75% 
of deaths related to skin cancer. In addition, the incidence of melanoma is increasing faster than that of any 
other cancer. Consequently, there is an increased demand for accurate diagnosis, prognosis, and treatment 
of melanoma.  
The thickness of a melanoma is a critical parameter for determining definitive treatment and prognosis 
[112]. Based on its thickness, the tumor (T) classification in the tumor-node-metastasis (TNM) staging 
system can be further divided into T1 (≤ 1.0 mm), T2 (1.01-2.0 mm), T3 (2.01-4.0 mm), and T4 (>4.0 mm). 
As the thickness increases, so do the chances for developing metastatic disease, and thus, disease mortality. 
Current diagnoses are dependent upon clinical suspicion, subsequent biopsy, and histologic examination. 
It has been shown that clinical examination alone may miss certain tumors, and conversely, many benign 
lesions may be unnecessarily biopsied [113, 114]. In trained hands, the use of handheld dermoscopy in the 
clinic has aided in the diagnosis of melanoma by facilitating the evaluation of surface characteristics of 
pigmented lesions [115]. It does not, however, enable the determination of tumor thickness and vertical 
growth of the melanoma, which are important tumor characteristics when it comes to determining surgical 
treatment.  In fact, the surgeon is often met with the confounding situation where a pigmented lesion may 
be partially biopsied and the diagnosis of melanoma is made. Consequently, the true tumor depth may not 
be determined due to sampling only part of the tumor, leading to an inaccurate measurement. Thus, a wide 
local excision (WLE) based upon a provisional tumor depth may not be appropriate, and a second surgery 
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may be required to adequately treat the tumor. Thus, a precise in vivo measurement of tumor depth, prior 
to definitive surgery, would facilitate appropriate patient treatment and help avoid further surgeries. 
In the past few years, several noninvasive imaging techniques have been developed for melanoma 
diagnoses. However, all of them have limitations. Optical methods, such as dermoscopy [115], total-body 
photography (TBP) [116], optical coherence tomography [117], scanning confocal microscopy [118], and 
two-photon microscopy [119], do not have sufficient penetration to determine melanoma depth because 
they can image only in the ballistic regime. High frequency ultrasound can provide deeper penetration than 
optical methods [120]. However, because there is often no sufficient difference in acoustic impedance 
between melanoma and normal tissues, the image contrast for melanoma is poor. Magnetic resonance 
imaging (MRI) and positron emission tomography (PET) have also been used in melanoma diagnoses [121, 
122]. However, they are both expensive and have poor resolution in the skin. Meanwhile, PET has to use 
tracers for sufficient contrast and can only detect tumors as large as ~1 cm in dimension, which 
encompasses only a tiny set of T4 primary melanomas and misses all T1–T3 ones.  
Recently, photoacoustic microscopy (PAM) has shown strong ability in detecting skin vasculatures with 
high contrast and deep penetration. In PAM, short laser pulses illuminate the object. Following the 
absorption of photons, ultrasonic waves are induced thermoelastically through the photoacoustic (PA) 
effect. Because melanin in most melanomas has a very broad and strong absorption spectrum, it can be 
imaged by PAM with high contrast. Meanwhile, because acoustic scattering is low in the tissue, high 
resolution can be achieved with deep penetration. 
Previously, we reported that cutaneous pigmented lesions, melanoma, and the surrounding vasculature 
could be successfully detected by using dual-wavelength PAM [123]. In that study, light was transmitted 
through the whole melanoma, resulting in a high attenuation, with only very few photons reaching the base 
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of the melanoma (true tumor depth). In the end, PA signals were very strong from the surface of the tumor 
but very weak from the deepest portion. The experimental results showed that a melanoma phantom with 
a maximum thickness of 1.27 mm could be imaged, which covered only the T1 classification. Using a 
similar configuration, other studies on melanoma detection can be found elsewhere. In this report, we 
describe a new PAM system with more efficient light illumination. By allowing light to bypass the center 
of the tumor, more photons reach the inferior depth of the melanoma. Equally important, this system is 
designed to be handheld, facilitating clinical usage. 
 
Figure 6.1 Experimental handheld PAM system. (a) Schematic of the handheld PAM system. (b) Components held by the 
translation stage in the handheld probe. (c) A photograph of the handheld probe. 
Methods  Figure 6.1(a) shows a schematic of the handheld PAM system. A Q-switched pulsed laser 
(Brilliant B, Quantel, Les Ulis, France) generates light at 532 nm at 10 Hz as the input for the dye cell. The 
output light of the dye cell is at 650 nm wavelength, where melanoma has high absorption, but both blood 
and water have low absorption. A lens couples the free-space light into an optical fiber bundle 
(LightGuideOptics, Rheinbach, Germany), with output fibers arranged in a circle around a focused 
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ultrasonic transducer (IS2502HR, CTS Valpey, Elkhart, Indiana). Compared to our previous PAM system, 
the light is delivered into the tissue normally instead of obliquely. Thus, the light propagates around the 
melanoma instead of going through it. Since the surrounding tissue has high optical scattering but low 
absorption, light reaching the bottom boundary of the melanoma is increased. The incident beam has an 
annular shape with 8 mm inner and 20 mm outer diameters. The optical fluence on the skin surface was 
estimated to be 15 mJ/cm2, which was smaller than the American National Standard Institute (ANSI) limit 
(20 mJ/cm2).  The transducer, with 25 MHz central frequency and 100% nominal bandwidth, detects the 
PA signals. The focal length and diameter of the detector are 12.7 mm and 6.4 mm, respectively, yielding 
a numerical aperture (NA) of 0.25. Both the optical fibers and transducer are fixed on a motorized 
translation stage (Figure 6.1(b)). Each laser pulse generates a one-dimensional depth-resolved image (A-
line). A two-dimensional cross sectional image is acquired by linear scanning of the region of interest. As 
shown in Figures 6.1(a) and (b), the motor, translation stage, ultrasonic transducer, and optical fibers are all 
incorporated in a handheld probe for easy operation. A photograph of the handheld probe is shown in Figure 
6.1(c). 
 
Figure 6.2 Monte Carlo simulations of the old and new PAM systems for melanoma imaging. Melanoma phantom and light 
illumination methods used in the simulations of the old (a) and new (b) systems. The red arrows show the incident angles and 
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areas of the light used in the Monte Carlo simulations. Specific heat absorption (Ae) distributions in the old (c) and new (d) PAM 
systems with the same incident energy. (e) Averaged Ae in the black-dashed-square areas (shown in (a-d)) at the bottom 
boundary of the melanoma phantoms in (c) (blue line) and (d) (red dotted line) showing that the melanoma is much more 
strongly illuminated at the bottom boundary using the new PAM system. 
Results  We use Monte Carlo simulations to show the advantage of the new light illumination mechanism. 
Figure 6.2(a) represents the old light illumination mechanism (hereinafter referred to as case 1). The 
incident angle was set to 45°, which was typical in the previous PAM system. Figure 6.2(b) shows the new 
light illumination mechanism (hereinafter referred to as case 2). In both simulations, the same incident 
energies were used. The same melanoma phantom, with 1 mm thickness and 6 mm diameter, was used in 
both simulations. The simulation parameters (absorption coefficient of the melanoma phantom, 70 cm-1; 
absorption coefficient of the background, 0.1 cm-1; scattering coefficients of the melanoma phantom and 
background, 100 cm-1; scattering anisotropy of the melanoma phantom and background, 0.9) were selected 
based on normal tissue optical properties at 650 nm wavelength. As shown in Figure 6.2(c), in case 1, the 
specific optical absorption (Ae) decreases sharply in the melanoma phantom in the depth direction. 
However, as shown in Figure 6.2(d), in case 2, Ae actually increases in the melanoma phantom in the depth 
direction. As shown in Figures 6.2(a-d), the same black-dashed-square area was chosen to calculate an 
average Ae at the bottom boundary of the melanoma phantoms for comparison between case 1 and case 2. 
The average Ae is shown in Figure 6.2(e). Although the average Ae at the bottom boundary of the melanoma 
in the black-dashed-square area was maximized by aligning the light beam in case 1 (shown in Figure 
6.2(a)), it is still 1660 times weaker than that in case 2. In both thermal and stress confinements, the PA 
signal is proportional to Ae. Thus, the PA signal in case 2 is 1660 times stronger than that in case 1. Because 
the light delivery is the only difference between the systems, their noise levels should be the same. Thus, 
the corresponding signal-to-noise ratio of the melanoma at the bottom boundary in the black-dashed-square 
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area in case 2 is 1660 times greater than that in case 1. The results show that, with the new illumination 
mechanism, the bottom boundary of the melanoma can be much more sensitively detected.  
 
Figure 6.3 Spatial resolutions of the current PAM system. PA amplitudes in the lateral x (a) and axial z (b) directions. The full 
widths at half maximum are 230 μm in (a) and 59 μm in (b). 
We first used a human hair as a line target to measure the lateral resolution of this handheld PAM system. 
As shown in Figure 6.3(a), the full width at half maximum (FWHM) of the line spread function indicates 
a lateral resolution of 230 μm. Because of the large thickness of the hair (80 μm), the measured lateral 
resolution is slightly larger than the theoretical value (0.72λ0/NA = 173 μm, where λ0 is the center acoustic 
wavelength of the transducer). We next used a thin ink layer to measure the axial resolution. Taking the 
FWHM of the PA amplitude in the axial direction, we estimated the axial resolution as 59 μm (Fig. 3(b)), 
which is close to the theoretical value (0.88vs/Δf = 53 μm, where vs is the sound speed in soft tissue, and Δf 
is the frequency bandwidth of the transducer). 
Phantom experiments were conducted to demonstrate the ability of the handheld PAM system to measure 
deep melanomas. Three different diameters (7 mm, 9.5 mm, and 14 mm) of melanoma phantoms were 
prepared with varied thicknesses, shown in Figures 6.4(a)-(c). All the phantoms were made from a black 
ink and gelatin mixture, which had an absorption coefficient of 70 cm-1 at 650 nm, close to the real 
melanoma absorption coefficient. The background was made of a gelatin and intralipid mixture with a high 
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scattering coefficient to mimic real tissue. As shown in Figures 6.4(a)-(c), our handheld system successfully 
detected both the top and bottom boundaries of all the melanoma phantoms. The maximum and minimum 
detected thicknesses of the phantoms were 0.7 mm and 4.1 mm, respectively. Thus, melanoma phantoms 
with all the T-classifications in the staging system have been measured. Figure 6.4(d) shows that our 
measured thicknesses agreed well with the preset values. Thus, the handheld PAM system can image 
deeply seated melanoma phantoms with high accuracy. 
 
Figure 6.4 Handheld PAM of melanoma phantoms. Photos of melanoma phantoms with different diameters ((a), 7 mm; (b), 9.5 
mm; and (c), 14 mm). (a1-a4), (b1-b4), and (c1-c4): PAM images of different thicknesses of melanoma phantoms with the same 
diameter as in (a), (b), and (c), respectively. (d) Measured thicknesses of melanoma phantoms versus preset thicknesses. 
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Figure 6.5 Handheld PAM of melanoma in a nude mouse in vivo. (a) PAM image of the melanoma clearly showing both the top 
and bottom boundaries. The red dots outline the melanoma according to the shape of the excised melanoma (red dots) in its 
photograph (b). Photograph of the melanoma taken in vivo (c). 
We also imaged mice with melanoma to show the in vivo detection ability of the handheld PAM system. 
Here we focused only on imaging deep melanoma to show the advantage of the new PAM system over our 
previous system. Melanoma B16 cells were subcutaneously injected into a nude mouse on the dorsal side 
(Hsd:Athymic Nude-Foxn1NU, Harlan Co.; body weight: 20 g) to grow melanoma in the skin. All 
experimental animal procedures were carried out in conformity with the laboratory animal protocol 
approved by the School of Medicine Animal Studies Committee of Washington University in St. Louis. 
During image acquisition, the animal, warmed by an infrared lamp, was kept motionless using a breathing 
anesthesia system (E-Z Anesthesia, Euthanex). Figure 6.5(a) shows that a melanoma with 3.66 mm 
thickness was imaged by our handheld system. Both the top and bottom boundaries of the melanoma and 
the skin surface can be clearly seen. Shown in Figure 6.5(b), the real thickness of the melanoma was 
measured to be 3.75 mm after excision, which is very close to our noninvasive measurement. A photograph 
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of the melanoma in vivo is shown in Figure 6.5(c). Therefore, the handheld PAM system can accurately 
detect the depth of deeply seated melanoma in vivo. 
Discussion  Compared to our previous PAM system for melanoma imaging, the new system can detect the 
depth of thicker melanomas by bypassing light around the tumor. In addition, a handheld design makes our 
new PAM system more suitable for clinical application. As shown in the phantom experiment, melanoma 
as thick as 4.1 mm can be detected, and in the in vivo experiment, melanoma with 3.75 mm thickness was 
imaged. Our measurements also show very high accuracy. As important, the improvement of the handheld 
system includes increasing the imaging speed. The current system employs a 10 Hz laser, which limits the 
imaging speed. 10 seconds are needed to scan a 10 mm length along the lateral direction with a step size of 
100 μm. For clinical use, a rapid imaging system is always preferred, which can be achieved by using a 
pump laser with high pulse repetition rate (e.g., 1 kHz) or using a handheld linear array probe. We propose 
that the use of handheld PAM imaging, to aid in the determination of tumor depth, will facilitate the surgical 
treatment management of melanoma. 
6.2 Handheld Photoacoustic Probe to Detect both Melanoma Depth and Volume at High Speed in Vivo 
Background  In the previous section, we reported that, in a murine xenograft melanoma model, 
tumor thickness can be accurately determined in vivo using a handheld photoacoustic probe. In 
that study, a single ultrasonic transducer and a 10 Hz laser were employed, limiting the imaging 
speed to around one frame per ten seconds. In addition, only the horizontal boundaries of the tumor 
could be detected due to the limited view angle of the focused transducer. To address these 
limitations, we next employed an ultrasonic transducer-array-based photoacoustic probe to detect 
melanoma depth, as described herein. The imaging speed can be increased to five frames per 
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second by using a 20 Hz laser. Using this probe and employing the large acceptance angle of the 
transducer array in the imaging plane, nearly the entire perimeter of the melanoma could be 
assessed. Furthermore, by simply adding a one-dimensional scanning stage, three-dimensional (3D) 
measurements of the melanoma could be obtained while the small footprint and convenience of 
the handheld device are maintained. With its ability to detect the margins in 3 axes, the array-based 
probe can be further used to determine the volume of a melanoma. It has been proposed that, 
similar to other solid tumors, melanoma volume may prove to be an excellent prognostic indicator 
— probably superior to Breslow’s depth. In this section, we first theoretically demonstrate that the 
linear-array-based probe can be used to determine and measure nearly the entire melanoma 
boundary, while the single ultrasonic transducer-based probe can detect only the horizontal 
boundary. Then we experimentally prove the ability of the linear-array-based probe to measure 
melanomas in phantoms, ex vivo, and in vivo. 
 
Figure 6.6 Schematic diagram of the LZ250 linear transducer array with optical fiber bundle integrated. (a) View 
from the elevational direction (x). (b) View of the transducer array’s head (enclosed by a dashed box in (a)) from the 
lateral direction (y). 
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Method  Figure 6.6 shows a schematic of the linear-array-based photoacoustic probe for 
melanoma imaging. A linear-array transducer (LZ250, Visualsonics Inc.), with a central frequency 
of 21 MHz and a 55% bandwidth, detected the photoacoustic signals. The transducer array 
contained 256 elements, and had a size of 23 mm × 3 mm, as shown in Figure 6.6. Each element 
of the array was cylindrically focused, and the focal length was 15 mm. A tunable optical 
parametric oscillator laser with a 20 Hz pulse repetition rate was the light source and was coupled 
into an optical fiber bundle. In our experiments, for melanoma imaging, the wavelength was set to 
680 nm, where melanin absorbs much more strongly than blood. The optical fiber bundle and an 
ultrasound cable were incorporated into the same package with the linear transducer array. The 
beam incident angle was 30° with respect to the imaging plane. The optical fluence on the skin 
surface was estimated to be 10 mJ/cm2, which was less than the safety limit set by the American 
National Standard Institute (ANSI) (20 mJ/cm2) at this wavelength. Each laser pulse generated a 
two-dimensional image. To get a 3D PA image of the melanoma, the transducer array was scanned 
linearly along its elevational direction (x axis) by a motorized stage. An imaging station (Vevo 
LAZR, Visualsonics Inc.) displayed the photoacoustic images at five frames/second. The raw data 
was then exported to a computer for image reconstruction and analysis. 
 
Figure 6.7 Simulation of the single focused ultrasonic transducer and the linear array. (a) Preset energy deposition 
distribution (Ae). Recovered Ae by the single focused ultrasonic transducer (b) and by the linear array transducer (c). 
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Figure 6.8 Response characteristics of the linear-array probe. (a) Maximum amplitude projection of the two crossed 
6-μm-diameter carbon fibers. The diameters differ because of the directional resolution differences. (b) Cross-
section image of the vertical carbon fiber along the dashed line in (a). Experimental data and Gaussian fits of the PA 
amplitude distributions along the (c) x, (d) y, and (e) z directions. 
We first simulated and compared the single focused ultrasonic transducer described previously 
with the array used in this paper. The simulation was conducted with the k-space pseudo-spectral 
method, in which the acoustic wave equation was modeled and solved in k-space, utilizing the 
benefits of fast Fourier transformation. For the single focused ultrasonic transducer, the central 
frequency, bandwidth, focal length, and diameter were 25 MHz, 100%, 12.7 mm, and 6.4 mm, 
respectively. The parameters of the array have been described above. Figure 6.7(a) shows the 
melanoma mimicking target, a half disk with a radius of 2 mm. To form the image, we raster 
scanned the single focused ultrasonic transducer and combined the adjacent A-lines, while a time-
reversal reconstruction method was used for the array system. In the time reversal method, the 
received pressure data were used as boundary conditions and the acoustic waves were propagated 
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in time-reversed order to find the pressure map at the initial time. Figure 6.7(b) shows that only 
the horizontal boundaries of the target are recovered by the single transducer based system. In 
contrast, almost the entire boundary of the target is recovered using the linear array for detection 
(Figure 6.7c). In addition, because the linear array scan does not need to be performed, the imaging 
speed can be significantly improved.  
 
Figure 6.9 Linear-array-based PA images of melanoma phantoms. (a) Photo of the melanoma phantoms. (b1-b7) and 
(c1-c7) correspond to the melanoma phantoms 1-7 in (a). Melanoma phantom images acquired by PA (b1-b7) and a 
standard optical microscope (c1-c7). 
The spatial resolution of the linear-array based PA probe was then quantified by imaging two 
crossed 6-μm-diameter carbon fibers, shown in Figures 6.8(a-b). The carbon fibers were placed in 
the x-y plane at a distance of 9 mm from the surface of the linear transducer array. Figures 6.8(c)-
(e) show both the fitting curves and PA amplitude distributions along the elevational (x), lateral 
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(y), and axial (z) directions. The full width at half maximum (FWHM) values, which are also 
spatial resolutions, are 1237 μm, 119 μm, and 86 μm in the elevational, lateral, and axial directions, 
respectively. 
Phantom experiments were then conducted to show the ability of the linear-array-based PA probe 
to measure melanoma thickness (depth) and calculate tumor volume (size). As shown in Figure 
6.9(a), melanoma phantoms of varying thicknesses and volumes were prepared. All the phantoms 
were made from a black ink and agar mixture, which had an absorption coefficient of 70 cm–1 at 
680 nm, close to the actual typical melanoma absorption coefficient. To mimic human tissue, the 
background was made of an agar and intralipid mixture with a scattering coefficient around 100 
cm–1 and a scattering anisotropy of ~0.9. To facilitate optimal comparison of melanoma phantoms, 
 
Figure 6.10 Depth (a) and volume (b) quantification of melanoma phantoms. Blue dots: experimental measurements. 
Red lines: ideal line if the PA measurements are identical to the standard measurements. 
we took the maximum-amplitude-projections of the 3D PA images along the elevational direction 
of the linear array, as shown in Figure 6.9(b1-b7). Immediately following the array-based 
experiments, melanoma phantoms were carefully removed from the agar/intralipid mixture, and 
corresponding gross images were taken using a standard microscope (EZ4 Stereo microscope, 
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Leica), as shown in Figures 6.9(c1-c7). There is an excellent correlation between the PA and gross 
images, demonstrating the ability of this system to accurately reproduce the phantom in situ. To 
further demonstrate the accuracy of the PA system and thus its potential for in vivo imaging, we 
then calculated both the depth and volume of these melanoma phantoms (Figure 6.10). The 
thickness and volume of the melanoma phantoms measured by the standard microscope and a 
graduated cylinder, respectively, served as the gold standards. In the PA measurements, to quantify 
the depth, the 6 dB threshold was used to separate the melanoma from the background. To quantify 
the volume, the 3D melanoma images were first downsampled. The downsampled image pixel size 
was equal to the resolution in each direction. The downsampled images were then thresholded at 
6 dB of the noise level to create melanoma boundaries. In the end, the volume was calculated by 
integrating the voxels inside the melanoma. We show that both the depths and volumes measured 
by our system agree well with the standard values, indicating that our linear-array-based PA probe 
can detect both the depth and volume of deeply seated melanoma in situ with high accuracy. 
We then performed experiments ex vivo to determine the accuracy of our system for thickness 
(depth) measurement, and volume calculation. For these experiments, we used a murine xenograft 
model where B16 melanoma cells were subcutaneously injected into the dorsal surface of nude 
mice (Hsd:Athymic Nude-Foxn1NU, Harlan Co.; average body weight: 20 g). All experimental 
animal procedures were carried out in conformity with the laboratory animal protocol approved 
by the Animal Studies Committee of Washington University in St. Louis. Tumors were allowed 
to grow spontaneously for 15 days, and the mice were then sacrificed. Fresh tumors excised from 
nude mice were embedded in the agar and intralipid mixture, prepared as described earlier (Figure 
6.11a). Imaging and processing was then performed as in the phantom experiments. Similarly, the 
ex vivo PA images of the melanomas are representative of the tumors as shown in Figures 6.11(b) 
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and (c). Again, the thickness and volume values calculated from the images are in accordance with 
the preset values (shown in Figure 6.12). Thus, we conclude that our system should be able to 
accurately image deep melanomas in vivo. 
 
Figure 6.11 Linear-array-based PA images of ex vivo melanomas. (a) A photo of the ex vivo melanomas. (b1-b6) and 
(c1-c6) correspond to the melanoma phantoms 1-6 in (a). Melanoma images acquired by PA (b1-b6) and a standard 
optical microscope (c1-c6). 
 
Figure 6.12 Depth (a) and volume (b) quantification of ex vivo melanomas. Blue dots: experimental measurements. 
Red lines: ideal line if the PA measurements are identical to the standard measurements. 
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Finally, we imaged mice with melanoma in vivo to show the detection ability of the linear-array-
based PA probe. We again employed the murine xenograft model using B16 melanoma cells in 
nude mice. For image acquisition, mice were anesthetized and kept motionless using a breathing 
anesthesia system (E-Z Anesthesia, Euthanex), while body temperature was maintained by an 
electric heating pad. Each measurement was repeated at day 3 and day 6 following the injection of 
cells (Figures 6.13a, b), and the rate of growth (ROG) was calculated. Again the detected 
melanoma can be clearly distinguished from the surrounding soft tissue. The depth and volume of 
the melanoma at day 3 and day 6 were measured to be 1.32 mm and 22.365 mm3, and 2.77 mm 
and 71.931 mm3, respectively. The depth-based and volume-based ROG were calculated to be 0.48 
mm/day and 16.555 mm3/day, respectively. 
 
Figure 6.13 Linear-array-based PA images of melanoma acquired in vivo on day 3 (a) and day 6 (b). 
6.3 Handheld Photoacoustic Probe for Noninvasive Determination of Melanoma Depth in Patients 
Method  In this section, we applied the linear array probe for melanoma patient imaging. In our 
study, 10 patients were recruited and a total 13 lesions were imaged. Benefits and risks of our 
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study were explained to the patients in detail. A written consent was obtained for the procedure. 
For each patient, we first imaged the melanoma with our PAT probe. Then an excisional biopsy 
was performed to extract the true melanoma depth. In these 13 lesions, there were 5 cases with a 
prior incisional biopsy. When analyzing our results, we found that among the 13 lesions, one lesion 
was not melanoma, and one lesion was very big (>10 mm), which was beyond the maximum 
imaging depth of this PAT probe for melanoma. Thus, we excluded these two cases in our final 
data analysis and focused on whether the PAT probe can be used for depth quantification of 
relatively shadow melanomas (i.e., <10 mm). All methods and experimental procedures were 
carried out in accordance with the guidelines of The Institutional Review Board of Washington 
University in St. Louis.  
 
Figure 6.14  PAT of melanoma in patients. (a) Melanoma image acquired with PAT, clearly showing the melanoma 
and skin surface. (b) Photograph of melanoma in patient. (c) Histologic examination of the melanoma, showing its 
true depth. 
A typical melanoma image acquired by PAT is shown in Figure 6.14(a), where the whole 
melanoma as well as the skin surface can be clearly seen. Thus, the melanoma depth information 
can be accurately recovered. In this case, the PAT-measured melanoma depth is 1.9 mm. Figure 
6.14(b) shows a photograph of the melanoma in the patient before excision. Immediately after the 
PAT experiment, an excisional biopsy was performed to determine the true tumor depth, as shown 
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in Figure 6.14(c). Based on the histology result, the melanoma depth was 1.67 mm. Note that in 
the process of fixation, the specimen may have shrunk by 30% of its volume, which corresponds 
to around 12% shrinkage in depth. Taking the shrinkage into account, a melanoma depth in vivo 
(based on PAT) of 1.9 mm actually corresponds to the 1.67 mm depth of melanoma ex vivo, which 
exactly matches the histological measurement. Thus, we demonstrated that PAT can measure 
melanoma depth noninvasively and accurately in patients. 
 
Figure 6.15 PAT-measured depth of all melanomas, showing concordance with the histologic results. In addition, 
the average PAT-based depth is more accurate than the depth from incisional biopsy. Black line: ideal line if the 
PAT/incisional measurements are identical to the excisional results. Red circles: PAT measurements. Blue squares: 
incisional measurements (initial biopsy). 
Figure 6.15 shows the results for all 11 melanomas. The maximum and minimum measured 
melanoma depths are 5 mm and 0.2 mm, respectively. Depth values measured by PAT are in good 
accord with the excisional biopsy results: For all lesions, the mean absolute error (MAE) was 0.18 
mm. We also analyzed the data for melanomas with prior incisional biopsies. In the five patients 
who underwent diagnostic biopsy prior to PAT followed by wide local excision, PAT yielded more 
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accurate depths than the initial biopsy. The MAE for the PAT measurements was 0.14 mm, smaller 
than the MAE of 0.21 mm for the incisional biopsy. Thus, we show that PAT is an effective 
imaging tool to accurately recover melanoma depth information and guide definitive surgical 
intervention. 
Discussion  In this work, melanomas deeper than 10 mm could not be imaged clearly, especially 
the bottom part. The main reason is the strong light attenuation in the melanoma, leading to very 
few photons reaching the base of the melanoma and thus very weak signals from the deepest 
portion. One potential solution would include improving the light illumination efficiency, e.g., 
allowing light to bypass the center of the tumor. 
We recognize that according to our results, PAT did not alter, but rather confirmed, current surgical 
treatment based upon provisional Breslow depth. However, as shown in our experimental results, 
PAT yielded greater accuracy than the incisional biopsy in measuring melanoma depth. A larger 
patient population would be the next step in improving utility of this technology and fine tuning 
the technique. PAT technology is non-invasive, provides high contrast for deep melanoma 
imaging, and fit easily in a clinic or surgical suite.  Ultimately, PAT technology may be an adjunct 
to surgical planning for patients with pigmented lesions, allowing more accurate and earlier 
assessment of melanoma depth to improve treatment of this aggressive and deadly malignancy. 
6.4 Conclusions 
In this chapter, we first developed a handheld PA probe for melanoma depth measurement in a 
mouse in vivo. With that probe, melanoma as thick as 4.1 mm could be detected, and in the in vivo 
experiment, melanoma with 3.75 mm thickness was imaged. Our measurements also show very 
high accuracy. To improve the imaging speed, we next applied a handheld linear array probe to 
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measure both melanoma depth and volume in vivo. Compared to the single ultrasonic transducer 
based system, the linear-array-based system can detect melanoma with an order of magnitude 
increase in imaging speed. In addition, because of the large acceptance angle of the linear 
ultrasonic transducer array, nearly the entire melanoma can be detected in 3D, as opposed to only 
the horizontal boundary. Finally, we applied this array probe for imaging 11 melanomas in 
patients. As shown in our experimental results, PAT yielded greater accuracy than incisional 
biopsy in measuring melanoma depth. 
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Chapter 7 Summary 
This dissertation has described the advance of PAT to translational studies and applications. We 
first improved the resolution and penetration depth of OR-PAM and applied it to count red blood 
cells and to map bilirubin. We then developed and applied PAT systems to study pain, quantify 
blood flow, image the brain, and measure melanoma depth in humans. 
In chapter 2, we used glycerol as an optical clearing agent in OR-PAM. Our results show that the 
imaging performance of OR-PAM can be greatly enhanced by optical clearing, both in vitro and 
in vivo. We then applied quantitative multi-wavelength PAM to detect bilirubin concentration and 
distribution simultaneously. By measuring tissue-mimicking phantoms with different bilirubin 
concentrations, we showed that the root-mean-square error of prediction has was as low as 0.52 
and 0.83 mg/dL for pure bilirubin and for blood-mixed bilirubin detection (with 100% oxygen 
saturation), respectively. We further demonstrated the capability of the PAM system to image 
bilirubin distribution both with and without blood. Our results show that PAM has potential for 
noninvasive bilirubin monitoring in vivo, as well as for further clinical applications. Finally, we 
presented a calibration-free method to quantify the absolute particle concentration by statistically 
analyzing photoacoustic signals. We first derived a theoretical model, then applied it to 
quantitative measurement of different concentrations of various particles, including red blood 
cells. Finally, we performed in vivo experiments to demonstrate the potential of our method in 
biological applications. The experimental results agreed well with the predictions from the 
theoretical model, suggesting that our method can be used for noninvasive measurement of 
absolute particle concentrations in tissue without fluence calibration. 
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In chapter 3, we evaluated PAM’s use in assisting diagnoses and monitoring the progress and 
treatment outcome of CRPS. Blood vasculature and sO2 were imaged by PAM from eight adult 
patients with CRPS-1. For comparison, patients’ hands and cuticles were imaged both before and 
after stellate ganglion block (SGB). For all patients, both vascular structure and sO2 could be 
assessed by PAM. In addition, more vessels and stronger signals were observed after SGB. The 
results show that PAM can help diagnose and monitor CRPS.  
In chapter 4, we developed three flow measurement methods: cross-correlation-based flowmetry, 
saline-injection-based flowmetry, and cuffing-based flowmetry. Using the cross-correlation-based 
method, we measured flow velocity without calibration and quantified flow velocities in vessels 
with different structures in a mouse ear in vivo. Using the saline-injection-based method, we 
successfully measured blood flow velocity in the optical diffusive regime in a mouse tail in vivo. 
Finally, by applying the cuffing-based method, we achieved the first human deep blood flow 
measurement with PAT. 
In chapter 5, we successfully imaged a mouse brain in vivo. We first implemented a 5 MHz 
transducer array for brain imaging and detected representative features in the brain. However, 
because of the poor resolution of the 5 MHz array system, the image contrast was not high. To 
solve that problem, we later applied a 21 MHz array system for brain imaging and achieved high 
contrast brain vasculature images. We then built a 0.5 MHz PACT system for human brain 
imaging, and achieved good phantom images through a human skull. 
In chapter 6, we first developed handheld PAM to detect melanoma and determine tumor depth in 
nude mice in vivo. Compared to our previous PAM system for melanoma imaging, a new light 
delivery mechanism was introduced to improve light penetration. We showed that melanomas with 
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4.1 and 3.7 mm thicknesses can be successfully detected in phantom and in in vivo experiments, 
respectively. However, this system was slow. To improve the imaging speed, we applied a linear-
array-based photoacoustic probe to detect melanin-containing melanoma tumor depth and volume 
in nude mice in vivo. This system can image melanomas at five frames per second (fps), which is 
much faster than our previous handheld single transducer system (0.1 fps). We first theoretically 
showed that, in addition to the higher frame rate, almost the entire boundary of the melanoma can 
be detected by the linear-array-based probe, while only the horizontal boundary could be detected 
by the previous system. Then we demonstrated the ability of this linear-array-based system in 
measuring both the depth and volume of melanoma through phantom, ex vivo, and in vivo 
experiments. The volume detection ability also enabled us to accurately calculate the rate of growth 
of the tumor, which is an important parameter in quantifying its activity. Finally, we applied this 
array system in imaging melanoma in patients and achieved more accurate melanoma depth 
information than current incisional biopsy. 
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